1
|
Barker-Haliski M, Nishi T, White HS. Soticlestat, a novel cholesterol 24-hydroxylase inhibitor, modifies acute seizure burden and chronic epilepsy-related behavioral deficits following Theiler's virus infection in mice. Neuropharmacology 2023; 222:109310. [PMID: 36341806 DOI: 10.1016/j.neuropharm.2022.109310] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2022] [Revised: 10/17/2022] [Accepted: 10/24/2022] [Indexed: 11/06/2022]
Abstract
Temporal lobe epilepsy is the most common form of acquired epilepsy and can arise due to multiple inciting events, including central nervous system (CNS) infection. CNS infection with the Theiler's murine encephalomyelitis virus (TMEV) in male C57Bl/6J mice leads to acute, drug-resistant handling-induced seizures. Cholesterol 24-hydroxylase (CH24H) is a brain-specific enzyme that converts cholesterol into 24S-hydroxycholesterol; the primary mechanism of cholesterol catabolism in the brain. The novel CH24H inhibitor, soticlestat (SOT; or TAK-935), demonstrates the potential to restore excitatory/inhibitory balance in multiple preclinical models of hyperexcitability. This study thus sought to characterize the anticonvulsant potential of SOT in the TMEV model. Treatment with SOT (30 mg/kg, p.o.; n = 30) 0-7 days post-infection (DPI) reduced overall seizure burden and severity. SOT administration significantly delayed onset of infection-induced Racine stage 5 seizures, from 8.6 ± 0.6 (VEH-treated) to 10.8 ± 0.8 (SOT-treated) observation sessions. Infected mice were then allowed 36 days treatment-free recovery before assessing impact of earlier drug administration on epilepsy-related cognitive and behavioral comorbidities, including a non-habituated open field (OF) task. Total OF distance traveled was significantly less in SOT-treated mice compared to VEH-treated mice, suggesting attenuated TMEV-induced spatial memory deficits, or reduced chronic hyperexcitability. Mice with history of SOT treatment also spent significantly more time and traveled farther in the OF center, indicative of reduced epilepsy-induced anxiety-like behavior. These studies suggest that SOT is a mechanistically novel agent for symptomatic seizure control. Moreover, acute SOT administration during an epileptogenic insult may attenuate the resulting long-term behavioral comorbidities of epilepsy.
Collapse
Affiliation(s)
| | - Toshiya Nishi
- Research, Takeda Pharmaceutical Company Limited, Fujisawa, 251-8555, Japan; Takeda Pharmaceutical Company Limited, Cambridge, MA, 02139, USA.
| | - H Steve White
- University of Washington, Department of Pharmacy, Seattle, WA, USA
| |
Collapse
|
2
|
Salamone A, Terrone G, Di Sapia R, Balosso S, Ravizza T, Beltrame L, Craparotta I, Mannarino L, Cominesi SR, Rizzi M, Pauletti A, Marchini S, Porcu L, Zimmer TS, Aronica E, During M, Abrahams B, Kondo S, Nishi T, Vezzani A. Cholesterol 24-hydroxylase is a novel pharmacological target for anti-ictogenic and disease modification effects in epilepsy. Neurobiol Dis 2022; 173:105835. [PMID: 35932989 DOI: 10.1016/j.nbd.2022.105835] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2022] [Revised: 07/15/2022] [Accepted: 07/30/2022] [Indexed: 10/16/2022] Open
Abstract
Therapies for epilepsy mainly provide symptomatic control of seizures since most of the available drugs do not target disease mechanisms. Moreover, about one-third of patients fail to achieve seizure control. To address the clinical need for disease-modifying therapies, research should focus on targets which permit interventions finely balanced between optimal efficacy and safety. One potential candidate is the brain-specific enzyme cholesterol 24-hydroxylase. This enzyme converts cholesterol to 24S-hydroxycholesterol, a metabolite which among its biological roles modulates neuronal functions relevant for hyperexcitability underlying seizures. To study the role of cholesterol 24-hydroxylase in epileptogenesis, we administered soticlestat (TAK-935/OV935), a potent and selective brain-penetrant inhibitor of the enzyme, during the early disease phase in a mouse model of acquired epilepsy using a clinically relevant dose. During soticlestat treatment, the onset of epilepsy was delayed and the number of ensuing seizures was decreased by about 3-fold compared to vehicle-treated mice, as assessed by EEG monitoring. Notably, the therapeutic effect was maintained 6.5 weeks after drug wash-out when seizure number was reduced by about 4-fold and their duration by 2-fold. Soticlestat-treated mice showed neuroprotection of hippocampal CA1 neurons and hilar mossy cells as assessed by post-mortem brain histology. High throughput RNA-sequencing of hippocampal neurons and glia in mice treated with soticlestat during epileptogenesis showed that inhibition of cholesterol 24-hydroxylase did not directly affect the epileptogenic transcriptional network, but rather modulated a non-overlapping set of genes that might oppose the pathogenic mechanisms of the disease. In human temporal lobe epileptic foci, we determined that cholesterol 24-hydroxylase expression trends higher in neurons, similarly to epileptic mice, while the enzyme is ectopically induced in astrocytes compared to control specimens. Soticlestat reduced significantly the number of spontaneous seizures in chronic epileptic mice when was administered during established epilepsy. Data show that cholesterol 24-hydroxylase contributes to spontaneous seizures and is involved in disease progression, thus it represents a novel target for chronic seizures inhibition and disease-modification therapy in epilepsy.
Collapse
Affiliation(s)
- Alessia Salamone
- Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milano, Italy
| | - Gaetano Terrone
- Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milano, Italy
| | - Rossella Di Sapia
- Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milano, Italy
| | - Silvia Balosso
- Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milano, Italy
| | - Teresa Ravizza
- Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milano, Italy
| | - Luca Beltrame
- Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milano, Italy
| | - Ilaria Craparotta
- Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milano, Italy
| | - Laura Mannarino
- Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milano, Italy
| | - Sara Raimondi Cominesi
- Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milano, Italy
| | - Massimo Rizzi
- Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milano, Italy
| | - Alberto Pauletti
- Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milano, Italy
| | - Sergio Marchini
- Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milano, Italy
| | - Luca Porcu
- Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milano, Italy
| | - Till S Zimmer
- Department of Neuropathology, Amsterdam UMC, 1105 Amsterdam, the Netherlands
| | - Eleonora Aronica
- Department of Neuropathology, Amsterdam UMC, 1105 Amsterdam, the Netherlands; Stichting Epilepsie Instellingen Nederland (SEIN), 2103 Heemstede, the Netherlands
| | | | - Brett Abrahams
- Ovid Therapeutics, 10036 New York, NY, USA; Departments of Genetics and Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, 10461 Bronx, USA
| | - Shinichi Kondo
- Takeda Pharmaceutical Company Limited, 251-8555 Fujisawa, Japan
| | - Toshiya Nishi
- Takeda Pharmaceutical Company Limited, 251-8555 Fujisawa, Japan
| | - Annamaria Vezzani
- Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milano, Italy.
| |
Collapse
|
3
|
Ikeda S, Kajita Y, Miyamoto M, Matsumiya K, Ishii T, Nishi T, Gay SC, Lane W, Constantinescu CC, Alagille D, Papin C, Tamagnan G, Kuroita T, Koike T. Design and synthesis of aryl-piperidine derivatives as potent and selective PET tracers for cholesterol 24-hydroxylase (CH24H). Eur J Med Chem 2022; 240:114612. [PMID: 35863274 DOI: 10.1016/j.ejmech.2022.114612] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2022] [Revised: 07/07/2022] [Accepted: 07/10/2022] [Indexed: 11/03/2022]
Abstract
Cholesterol 24-hydroxylase (CH24H, CYP46A1) is a cytochrome P450 family enzyme that maintains the homeostasis of brain cholesterol. Soticlestat, a potent and selective CH24H inhibitor, is in development as a therapeutic agent for Dravet syndrome and Lennox-Gastaut syndrome. Herein, we report the discovery of aryl-piperidine derivatives as potent and selective CH24H positron emission tomography (PET) tracers which can be used for dose guidance of a clinical CH24H inhibitor and as a diagnostic tool for CH24H-related pathology. Starting from compound 1 (IC50 = 16 nM, logD = 1.7), which was reported as a CH24H inhibitor with lower lipophilicity, a18F-labeling site (3-fluoroazetidine) was incorporated by structure-based drug design (SBDD) utilizing the co-crystal structure of a compound 1 analog. Subsequent optimization to adjust key parameters for PET tracers, such as potency, lipophilicity, brain penetration, and unbound plasma protein binding, enabled compounds 3f (IC50 = 8.8 nM) and 3g (IC50 = 8.7 nM) as PET imaging candidates. Selectivity of these compounds for CH24H was validated by a brain distribution study using CH24H-WT and KO mice. In non-human primate PET imaging, [18F]3f and [18F]3g showed similar regional uptake in the brain, indicating that these tracers were specific to the CH24H-expressed regions and validated the expression of CH24H in the living brain by different tracers.
Collapse
Affiliation(s)
- Shuhei Ikeda
- Takeda Pharmaceutical Company Ltd., 26-1 Muraoka-Higashi, 2-Chome, Fujisawa, Kanagawa, 251-8555, Japan
| | - Yuichi Kajita
- Takeda Pharmaceutical Company Ltd., 26-1 Muraoka-Higashi, 2-Chome, Fujisawa, Kanagawa, 251-8555, Japan
| | - Maki Miyamoto
- Takeda Pharmaceutical Company Ltd., 26-1 Muraoka-Higashi, 2-Chome, Fujisawa, Kanagawa, 251-8555, Japan
| | - Kouta Matsumiya
- Takeda Pharmaceutical Company Ltd., 26-1 Muraoka-Higashi, 2-Chome, Fujisawa, Kanagawa, 251-8555, Japan
| | - Tsuyoshi Ishii
- Takeda Pharmaceutical Company Ltd., 26-1 Muraoka-Higashi, 2-Chome, Fujisawa, Kanagawa, 251-8555, Japan
| | - Toshiya Nishi
- Takeda Pharmaceutical Company Ltd., 26-1 Muraoka-Higashi, 2-Chome, Fujisawa, Kanagawa, 251-8555, Japan
| | - Sean C Gay
- Takeda California, Inc., 9625 Towne Centre Drive, San Diego, CA, 92121, United States
| | - Weston Lane
- Takeda California, Inc., 9625 Towne Centre Drive, San Diego, CA, 92121, United States
| | | | - David Alagille
- Invicro, LLC, 60 Temple Street, New Haven, CT, 06510, United States
| | - Caroline Papin
- Invicro, LLC, 60 Temple Street, New Haven, CT, 06510, United States
| | - Gilles Tamagnan
- Invicro, LLC, 60 Temple Street, New Haven, CT, 06510, United States
| | - Takanobu Kuroita
- Takeda Pharmaceutical Company Ltd., 26-1 Muraoka-Higashi, 2-Chome, Fujisawa, Kanagawa, 251-8555, Japan
| | - Tatsuki Koike
- Takeda Pharmaceutical Company Ltd., 26-1 Muraoka-Higashi, 2-Chome, Fujisawa, Kanagawa, 251-8555, Japan.
| |
Collapse
|
4
|
Nishi T, Metcalf CS, Fujimoto S, Hasegawa S, Miyamoto M, Sunahara E, Watanabe S, Kondo S, White HS. Anticonvulsive properties of soticlestat, a novel cholesterol 24-hydroxylase inhibitor. Epilepsia 2022; 63:1580-1590. [PMID: 35316533 PMCID: PMC9311151 DOI: 10.1111/epi.17232] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2021] [Revised: 03/10/2022] [Accepted: 03/18/2022] [Indexed: 12/02/2022]
Abstract
Objective The formation of 24S‐hydroxycholesterol is a brain‐specific mechanism of cholesterol catabolism catalyzed by cholesterol 24‐hydroxylase (CYP46A1, also known as CH24H). CH24H has been implicated in various biological mechanisms, whereas pharmacological lowering of 24S‐hydroxycholesterol has not been fully studied. Soticlestat is a novel small‐molecule inhibitor of CH24H. Its therapeutic potential was previously identified in a mouse model with an epileptic phenotype. In the present study, the anticonvulsive property of soticlestat was characterized in rodent models of epilepsy that have long been used to identify antiseizure medications. Methods The anticonvulsive property of soticlestat was investigated in maximal electroshock seizures (MES), pentylenetetrazol (PTZ) acute seizures, 6‐Hz psychomotor seizures, audiogenic seizures, amygdala kindling, PTZ kindling, and corneal kindling models. Soticlestat was characterized in a PTZ kindling model under steady‐state pharmacokinetics to relate its anticonvulsive effects to pharmacodynamics. Results Among models of acutely evoked seizures, whereas anticonvulsive effects of soticlestat were identified in Frings mice, a genetic model of audiogenic seizures, it was found ineffective in MES, acute PTZ seizures, and 6‐Hz seizures. The protective effects of soticlestat against audiogenic seizures increased with repetitive dosing. Soticlestat was also tested in models of progressive seizure severity. Soticlestat treatment delayed kindling acquisition, whereas fully kindled animals were not protected. Importantly, soticlestat suppressed the progression of seizure severity in correlation with 24S‐hydroxycholesterol lowering in the brain, suggesting that 24S‐hydroxycholesterol can be aggressively reduced to produce more potent effects on seizure development in kindling acquisition. Significance The data collectively suggest that soticlestat can ameliorate seizure symptoms through a mechanism distinct from conventional antiseizure medications. With its novel mechanism of action, soticlestat could constitute a novel class of antiseizure medications for treatment of intractable epilepsy disorders such as developmental and epileptic encephalopathy.
Collapse
Affiliation(s)
- Toshiya Nishi
- Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
| | - Cameron S Metcalf
- Department of Pharmacology and Toxicology, College of Pharmacy, University of Utah, Salt Lake City, UT, USA
| | - Shinji Fujimoto
- Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
| | - Shigeo Hasegawa
- Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
| | - Maki Miyamoto
- Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
| | - Eiji Sunahara
- Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
| | - Sayuri Watanabe
- Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
| | - Shinichi Kondo
- Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
| | - H Steve White
- Department of Pharmacy, School of Pharmacy, University of Washington, Seattle, WA, USA
| |
Collapse
|
5
|
Hashimoto T, Aikawa S, Akaishi T, Asano H, Bazzi M, Bennett DA, Berger M, Bosnar D, Butt AD, Curceanu C, Doriese WB, Durkin MS, Ezoe Y, Fowler JW, Fujioka H, Gard JD, Guaraldo C, Gustafsson FP, Han C, Hayakawa R, Hayano RS, Hayashi T, Hays-Wehle JP, Hilton GC, Hiraiwa T, Hiromoto M, Ichinohe Y, Iio M, Iizawa Y, Iliescu M, Ishimoto S, Ishisaki Y, Itahashi K, Iwasaki M, Ma Y, Murakami T, Nagatomi R, Nishi T, Noda H, Noumi H, Nunomura K, O'Neil GC, Ohashi T, Ohnishi H, Okada S, Outa H, Piscicchia K, Reintsema CD, Sada Y, Sakuma F, Sato M, Schmidt DR, Scordo A, Sekimoto M, Shi H, Shirotori K, Sirghi D, Sirghi F, Suzuki K, Swetz DS, Takamine A, Tanida K, Tatsuno H, Trippl C, Uhlig J, Ullom JN, Yamada S, Yamaga T, Yamazaki T, Zmeskal J. Measurements of Strong-Interaction Effects in Kaonic-Helium Isotopes at Sub-eV Precision with X-Ray Microcalorimeters. Phys Rev Lett 2022; 128:112503. [PMID: 35363014 DOI: 10.1103/physrevlett.128.112503] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/25/2021] [Accepted: 01/25/2022] [Indexed: 06/14/2023]
Abstract
We have measured the 3d→2p transition x rays of kaonic ^{3}He and ^{4}He atoms using superconducting transition-edge-sensor microcalorimeters with an energy resolution better than 6 eV (FWHM). We determined the energies to be 6224.5±0.4(stat)±0.2(syst) eV and 6463.7±0.3(stat)±0.1(syst) eV, and widths to be 2.5±1.0(stat)±0.4(syst) eV and 1.0±0.6(stat)±0.3(stat) eV, for kaonic ^{3}He and ^{4}He, respectively. These values are nearly 10 times more precise than in previous measurements. Our results exclude the large strong-interaction shifts and widths that are suggested by a coupled-channel approach and agree with calculations based on optical-potential models.
Collapse
Affiliation(s)
- T Hashimoto
- Advanced Science Research Center, Japan Atomic Energy Agency (JAEA), Tokai 319-1184, Japan
- RIKEN Cluster for Pioneering Research, RIKEN, Wako 351-0198, Japan
| | - S Aikawa
- Department of Physics, Tokyo Institute of Technology, Tokyo 152-8551, Japan
| | - T Akaishi
- Department of Physics, Osaka University, Toyonaka 560-0043, Japan
| | - H Asano
- RIKEN Cluster for Pioneering Research, RIKEN, Wako 351-0198, Japan
| | - M Bazzi
- Laboratori Nazionali di Frascati dell' INFN, Frascati I-00044, Italy
| | - D A Bennett
- National Institute of Standards and Technology, Boulder, Colorado 80305, USA
| | - M Berger
- Stefan-Meyer-Institut für subatomare Physik, Vienna A-1030, Austria
| | - D Bosnar
- Department of Physics, Faculty of Science, University of Zagreb, Zagreb 10000, Croatia
| | - A D Butt
- Politecnico di Milano, Dipartimento di Elettronica, Milano 20133, Italy
| | - C Curceanu
- Laboratori Nazionali di Frascati dell' INFN, Frascati I-00044, Italy
| | - W B Doriese
- National Institute of Standards and Technology, Boulder, Colorado 80305, USA
| | - M S Durkin
- National Institute of Standards and Technology, Boulder, Colorado 80305, USA
| | - Y Ezoe
- Department of Physics, Tokyo Metropolitan University, Tokyo 192-0397, Japan
| | - J W Fowler
- National Institute of Standards and Technology, Boulder, Colorado 80305, USA
| | - H Fujioka
- Department of Physics, Tokyo Institute of Technology, Tokyo 152-8551, Japan
| | - J D Gard
- National Institute of Standards and Technology, Boulder, Colorado 80305, USA
| | - C Guaraldo
- Laboratori Nazionali di Frascati dell' INFN, Frascati I-00044, Italy
| | - F P Gustafsson
- Stefan-Meyer-Institut für subatomare Physik, Vienna A-1030, Austria
| | - C Han
- RIKEN Cluster for Pioneering Research, RIKEN, Wako 351-0198, Japan
| | - R Hayakawa
- Department of Physics, Tokyo Metropolitan University, Tokyo 192-0397, Japan
| | - R S Hayano
- Department of Physics, The University of Tokyo, Tokyo 113-0033, Japan
| | - T Hayashi
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency, Sagamihara 252-5210, Japan
| | - J P Hays-Wehle
- National Institute of Standards and Technology, Boulder, Colorado 80305, USA
| | - G C Hilton
- National Institute of Standards and Technology, Boulder, Colorado 80305, USA
| | - T Hiraiwa
- Research Center for Nuclear Physics (RCNP), Osaka University, Ibaraki 567-0047, Japan
| | - M Hiromoto
- Department of Physics, Osaka University, Toyonaka 560-0043, Japan
| | - Y Ichinohe
- Department of Physics, Rikkyo University, Tokyo 171-8501, Japan
| | - M Iio
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan
| | - Y Iizawa
- Department of Physics, Tokyo Institute of Technology, Tokyo 152-8551, Japan
| | - M Iliescu
- Laboratori Nazionali di Frascati dell' INFN, Frascati I-00044, Italy
| | - S Ishimoto
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan
| | - Y Ishisaki
- Department of Physics, Tokyo Metropolitan University, Tokyo 192-0397, Japan
| | - K Itahashi
- RIKEN Cluster for Pioneering Research, RIKEN, Wako 351-0198, Japan
| | - M Iwasaki
- RIKEN Cluster for Pioneering Research, RIKEN, Wako 351-0198, Japan
| | - Y Ma
- RIKEN Cluster for Pioneering Research, RIKEN, Wako 351-0198, Japan
| | - T Murakami
- Department of Physics, The University of Tokyo, Tokyo 113-0033, Japan
| | - R Nagatomi
- Department of Physics, Osaka University, Toyonaka 560-0043, Japan
| | - T Nishi
- RIKEN Nishina Center for Accelerator-Based Science, RIKEN, Wako 351-0198, Japan
| | - H Noda
- Department of Earth and Space Science, Osaka University, Toyonaka 560-0043, Japan
| | - H Noumi
- Research Center for Nuclear Physics (RCNP), Osaka University, Ibaraki 567-0047, Japan
| | - K Nunomura
- Department of Physics, Tokyo Metropolitan University, Tokyo 192-0397, Japan
| | - G C O'Neil
- National Institute of Standards and Technology, Boulder, Colorado 80305, USA
| | - T Ohashi
- Department of Physics, Tokyo Metropolitan University, Tokyo 192-0397, Japan
| | - H Ohnishi
- Research Center for Electron Photon Science (ELPH), Tohoku University, Sendai 982-0826, Japan
| | - S Okada
- RIKEN Cluster for Pioneering Research, RIKEN, Wako 351-0198, Japan
- Engineering Science Laboratory, Chubu University, Kasugai 487-8501, Japan
| | - H Outa
- RIKEN Cluster for Pioneering Research, RIKEN, Wako 351-0198, Japan
| | - K Piscicchia
- Laboratori Nazionali di Frascati dell' INFN, Frascati I-00044, Italy
| | - C D Reintsema
- National Institute of Standards and Technology, Boulder, Colorado 80305, USA
| | - Y Sada
- Research Center for Electron Photon Science (ELPH), Tohoku University, Sendai 982-0826, Japan
| | - F Sakuma
- RIKEN Cluster for Pioneering Research, RIKEN, Wako 351-0198, Japan
| | - M Sato
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan
| | - D R Schmidt
- National Institute of Standards and Technology, Boulder, Colorado 80305, USA
| | - A Scordo
- Laboratori Nazionali di Frascati dell' INFN, Frascati I-00044, Italy
| | - M Sekimoto
- High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan
| | - H Shi
- Stefan-Meyer-Institut für subatomare Physik, Vienna A-1030, Austria
| | - K Shirotori
- Research Center for Nuclear Physics (RCNP), Osaka University, Ibaraki 567-0047, Japan
| | - D Sirghi
- Laboratori Nazionali di Frascati dell' INFN, Frascati I-00044, Italy
| | - F Sirghi
- Laboratori Nazionali di Frascati dell' INFN, Frascati I-00044, Italy
| | - K Suzuki
- Stefan-Meyer-Institut für subatomare Physik, Vienna A-1030, Austria
| | - D S Swetz
- National Institute of Standards and Technology, Boulder, Colorado 80305, USA
| | - A Takamine
- RIKEN Cluster for Pioneering Research, RIKEN, Wako 351-0198, Japan
| | - K Tanida
- Advanced Science Research Center, Japan Atomic Energy Agency (JAEA), Tokai 319-1184, Japan
| | - H Tatsuno
- Department of Physics, Tokyo Metropolitan University, Tokyo 192-0397, Japan
| | - C Trippl
- Stefan-Meyer-Institut für subatomare Physik, Vienna A-1030, Austria
| | - J Uhlig
- Chemical Physics, Lund University, Lund 22100, Sweden
| | - J N Ullom
- National Institute of Standards and Technology, Boulder, Colorado 80305, USA
| | - S Yamada
- Department of Physics, Rikkyo University, Tokyo 171-8501, Japan
| | - T Yamaga
- RIKEN Cluster for Pioneering Research, RIKEN, Wako 351-0198, Japan
| | - T Yamazaki
- Department of Physics, The University of Tokyo, Tokyo 113-0033, Japan
| | - J Zmeskal
- Stefan-Meyer-Institut für subatomare Physik, Vienna A-1030, Austria
| |
Collapse
|
6
|
Kajita Y, Ikeda S, Yoshikawa M, Fukuda H, Watanabe E, Yano J, Lane W, Miyamoto M, Ishii T, Nishi T, Koike T. Discovery of Novel 3-Piperidinyl Pyridine Derivatives as Highly Potent and Selective Cholesterol 24-Hydroxylase (CH24H) Inhibitors. J Med Chem 2022; 65:3343-3358. [PMID: 35166541 DOI: 10.1021/acs.jmedchem.1c01898] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Cholesterol 24-hydroxylase (CH24H or CYP46A1) is a brain-specific cytochrome P450 enzyme that metabolizes cholesterol into 24S-hydroxycholesterol (24HC) for regulating brain cholesterol homeostasis. For the development of a novel and potent CH24H inhibitor, we designed and synthesized 3,4-disubstituted pyridine derivatives using a structure-based drug design approach starting from compounds 1 (soticlestat) and 2 (thioperamide). Optimization of this series by focusing on ligand-lipophilicity efficiency value resulted in the discovery of 4-(4-methyl-1-pyrazolyl)pyridine derivative 17 (IC50 = 8.5 nM) as a potent and highly selective CH24H inhibitor. The X-ray crystal structure of CH24H in complex with compound 17 revealed a unique binding mode. Both blood-brain barrier penetration and reduction of 24HC levels (26% reduction) in the mouse brain were confirmed by oral administration of 17 at 30 mg/kg, indicating that 17 is a promising tool for the novel and selective inhibition of CH24H.
Collapse
Affiliation(s)
- Yuichi Kajita
- Research, Takeda Pharmaceutical Company Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Shuhei Ikeda
- Research, Takeda Pharmaceutical Company Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Masato Yoshikawa
- Research, Takeda Pharmaceutical Company Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Hiromi Fukuda
- Research, Takeda Pharmaceutical Company Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Etsurou Watanabe
- Research, Takeda Pharmaceutical Company Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Jason Yano
- Takeda California Inc., 9625 Towne Centre Drive, San Diego, California 92121, United States
| | - Weston Lane
- Takeda California Inc., 9625 Towne Centre Drive, San Diego, California 92121, United States
| | - Maki Miyamoto
- Research, Takeda Pharmaceutical Company Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Tsuyoshi Ishii
- Research, Takeda Pharmaceutical Company Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Toshiya Nishi
- Research, Takeda Pharmaceutical Company Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Tatsuki Koike
- Research, Takeda Pharmaceutical Company Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| |
Collapse
|
7
|
Hawkins NA, Jurado M, Thaxton TT, Duarte SE, Barse L, Tatsukawa T, Yamakawa K, Nishi T, Kondo S, Miyamoto M, Abrahams BS, During MJ, Kearney JA. Soticlestat, a novel cholesterol 24-hydroxylase inhibitor, reduces seizures and premature death in Dravet syndrome mice. Epilepsia 2021; 62:2845-2857. [PMID: 34510432 PMCID: PMC9291096 DOI: 10.1111/epi.17062] [Citation(s) in RCA: 25] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2021] [Revised: 08/23/2021] [Accepted: 08/23/2021] [Indexed: 02/06/2023]
Abstract
OBJECTIVE Dravet syndrome is a severe developmental and epileptic encephalopathy (DEE) most often caused by de novo pathogenic variants in SCN1A. Individuals with Dravet syndrome rarely achieve seizure control and have significantly elevated risk for sudden unexplained death in epilepsy (SUDEP). Heterozygous deletion of Scn1a in mice (Scn1a+/- ) recapitulates several core phenotypes, including temperature-dependent and spontaneous seizures, SUDEP, and behavioral abnormalities. Furthermore, Scn1a+/- mice exhibit a similar clinical response to standard anticonvulsants. Cholesterol 24-hydroxlase (CH24H) is a brain-specific enzyme responsible for cholesterol catabolism. Recent research has indicated the therapeutic potential of CH24H inhibition for diseases associated with neural excitation, including seizures. METHODS In this study, the novel compound soticlestat, a CH24H inhibitor, was administered to Scn1a+/- mice to investigate its ability to improve Dravet-like phenotypes in this preclinical model. RESULTS Soticlestat treatment reduced seizure burden, protected against hyperthermia-induced seizures, and completely prevented SUDEP in Scn1a+/- mice. Video-electroencephalography (EEG) analysis confirmed the ability of soticlestat to reduce occurrence of electroclinical seizures. SIGNIFICANCE This study demonstrates that soticlestat-mediated inhibition of CH24H provides therapeutic benefit for the treatment of Dravet syndrome in mice and has the potential for treatment of DEEs.
Collapse
Affiliation(s)
- Nicole A Hawkins
- Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
| | - Manuel Jurado
- Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
| | - Tyler T Thaxton
- Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
| | - Samantha E Duarte
- Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
| | - Levi Barse
- Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
| | - Tetsuya Tatsukawa
- Laboratory for Neurogenetics, RIKEN Brain Science Institute, Wako, Japan
| | - Kazuhiro Yamakawa
- Laboratory for Neurogenetics, RIKEN Brain Science Institute, Wako, Japan
| | - Toshiya Nishi
- Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Ltd, Fujisawa, Japan
| | - Shinichi Kondo
- Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Ltd, Fujisawa, Japan
| | - Maki Miyamoto
- Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Ltd, Fujisawa, Japan
| | | | | | - Jennifer A Kearney
- Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
| |
Collapse
|
8
|
Koike T, Yoshikawa M, Ando HK, Farnaby W, Nishi T, Watanabe E, Yano J, Miyamoto M, Kondo S, Ishii T, Kuroita T. Discovery of Soticlestat, a Potent and Selective Inhibitor for Cholesterol 24-Hydroxylase (CH24H). J Med Chem 2021; 64:12228-12244. [PMID: 34387987 DOI: 10.1021/acs.jmedchem.1c00864] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Cholesterol 24-hydroxylase (CH24H, CYP46A1), a brain-specific cytochrome P450 (CYP) family enzyme, plays a role in the homeostasis of brain cholesterol by converting cholesterol to 24S-hydroxycholesterol (24HC). Despite a wide range of potential of CH24H as a drug target, no potent and selective inhibitors have been identified. Here, we report on the structure-based drug design (SBDD) of novel 4-arylpyridine derivatives based on the X-ray co-crystal structure of hit derivative 1b. Optimization of 4-arylpyridine derivatives led us to identify 3v ((4-benzyl-4-hydroxypiperidin-1-yl)(2,4'-bipyridin-3-yl)methanone, IC50 = 7.4 nM) as a highly potent, selective, and brain-penetrant CH24H inhibitor. Following oral administration to mice, 3v resulted in a dose-dependent reduction of 24HC levels in the brain (1, 3, and 10 mg/kg). Compound 3v (soticlestat, also known as TAK-935) is currently under clinical investigation for the treatment of Dravet syndrome and Lennox-Gastaut syndrome as a novel drug class for epilepsies.
Collapse
Affiliation(s)
- Tatsuki Koike
- Research, Takeda Pharmaceutical Company Ltd., 26-1 Muraoka-Higashi, 2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Masato Yoshikawa
- Research, Takeda Pharmaceutical Company Ltd., 26-1 Muraoka-Higashi, 2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Haruhi Kamisaki Ando
- Research, Takeda Pharmaceutical Company Ltd., 26-1 Muraoka-Higashi, 2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| | - William Farnaby
- Research, Takeda Pharmaceutical Company Ltd., 26-1 Muraoka-Higashi, 2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Toshiya Nishi
- Research, Takeda Pharmaceutical Company Ltd., 26-1 Muraoka-Higashi, 2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Etsurou Watanabe
- Research, Takeda Pharmaceutical Company Ltd., 26-1 Muraoka-Higashi, 2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Jason Yano
- Takeda California Inc., 9625 Towne Centre Drive, San Diego, California 92121, United States
| | - Maki Miyamoto
- Research, Takeda Pharmaceutical Company Ltd., 26-1 Muraoka-Higashi, 2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Shigeru Kondo
- Research, Takeda Pharmaceutical Company Ltd., 26-1 Muraoka-Higashi, 2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Tsuyoshi Ishii
- Research, Takeda Pharmaceutical Company Ltd., 26-1 Muraoka-Higashi, 2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Takanobu Kuroita
- Research, Takeda Pharmaceutical Company Ltd., 26-1 Muraoka-Higashi, 2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| |
Collapse
|
9
|
Wong C, Nishi T, Ng M, Yong A, Ada C, Kakuta T, Barbato E, Waseda K, Amano T, Hirohata A, Fearon W. Elevated Microvascular Resistance in Conjunction With Reduced Coronary Flow Reserve Predicts Adverse Long-Term Outcomes After Percutaneous Coronary Intervention. Heart Lung Circ 2021. [DOI: 10.1016/j.hlc.2021.06.475] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
10
|
Tatekawa S, Shimamoto S, Nishi T, Tani M, Ohsima T, Onosaka S, Komeya Y, Yamashita Y, Tamari K, Ogawa K. PO-0853: The effect of the smoking cessation for radiation therapy of glottis carcinoma with monitoring CO. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00870-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
11
|
Hozumi T, Morimoto J, Nishi T, Takemoto K, Fujita S, Wada T, Shimamura K, Kashiawagi M, Shiono Y, Kuroi A, Matsuo Y, Ino Y, Kubo T, Tanaka A, Akasaka T. P1518 Relationship between post-operative asymptomatic status and reverse remodeling of large left atrium in patients with aortic stenosis who underwent aortic valve replacement. Eur Heart J Cardiovasc Imaging 2020. [DOI: 10.1093/ehjci/jez319.942] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Recently, we have reported that large left atrial volume (minimum left atrial volume index : LAVImin ≥30ml/m²) at end-diastole determined by direct exposure of left ventricular (LV) end-diastolic pressure can predict post-operative symptomatic status after aortic valve replacement (AVR) in aortic stenosis (AS) patients with high sensitivity and modest specificity. Reverse remodeling of large LAVImin after AVR may contribute to false positive for the prediction of post-operative symptomatic status in patients with AS.
Purpose
The purpose of this study was to evaluate relationship between post-operative symptomatic status and reverse remodeling of large LAVImin in patients with AS who underwent AVR.
Methods
The study population consisted of 75 patients with AS who underwent AVR and were followed up for 600 days after AVR, after the exclusion of the followings; atrial fibrillation, significant coronary artery disease, significant mitral valve disease, pacemaker rhythm, and inadequate echocardiographic images. We measured LAVImin by biplane Simpson"s method before and after AVR. Preoperative large LAVImin (≥30ml/m²) according to the previous study was observed in 32 (43%) of 75 patients. We divided these 32 patients into two groups according to the post-operative symptomatic status during the follow-up period.
Results
There was no significant difference in pre-operative LAVImin between patients with and without post-operative symptom (46.5 ± 13.4 vs 40.4 ± 8.6 ml/m²). On the other hand, post-operative LAVImin in patients without post-operative symptom was significantly smaller than that in patients with post-operative symptom (31.5 ± 8.6 vs 54.8 ± 14.0 ml/m², p < 0.01). While significant regression in LAVImin after AVR was observed in patients without post-operative symptom (40.4 ± 8.6 to 31.5 ± 8.6 ml/m², p < 0.05), no regression in LAVImin after AVR was observed in patients with post-operative symptom (46.5 ± 13.4 to 54.8 ± 14.0 ml/m²).
Conclusions
Reverse remodeling of large LAVmin in patients with AS who underwent AVR was observed in post-operative asymptomatic group, but not in symptomatic group. These results suggest that reverse remodeling of large LAVImin after AVR could contribute to the post-operative asymptomatic status in patients with AS who underwent AVR.
Collapse
Affiliation(s)
- T Hozumi
- Wakayama Medical University, Wakayama, Japan
| | - J Morimoto
- Wakayama Medical University, Wakayama, Japan
| | - T Nishi
- Wakayama Medical University, Wakayama, Japan
| | - K Takemoto
- Wakayama Medical University, Wakayama, Japan
| | - S Fujita
- Wakayama Medical University, Wakayama, Japan
| | - T Wada
- Wakayama Medical University, Wakayama, Japan
| | - K Shimamura
- Wakayama Medical University, Wakayama, Japan
| | | | - Y Shiono
- Wakayama Medical University, Wakayama, Japan
| | - A Kuroi
- Wakayama Medical University, Wakayama, Japan
| | - Y Matsuo
- Wakayama Medical University, Wakayama, Japan
| | - Y Ino
- Wakayama Medical University, Wakayama, Japan
| | - T Kubo
- Wakayama Medical University, Wakayama, Japan
| | - A Tanaka
- Wakayama Medical University, Wakayama, Japan
| | - T Akasaka
- Wakayama Medical University, Wakayama, Japan
| |
Collapse
|
12
|
Hozumi T, Nozawa Y, Takemoto K, Nishi T, Wada T, Maniwa N, Kashiwagi K, Shimamura K, Kuroi A, Matsuo Y, Kitabata H, Ino Y, Kubo T, Tanaka A, Akasaka T. P3365Relationship between early diastolic intra-ventricular pressure gradient shortly after aortic valve closure estimated by vector flow mapping and left ventricular diastolic untwisting rate in humans. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Early diastolic suction is an important determinant of early diastolic function. Previous studies using color Doppler M-mode and speckle-tracking echocardiography have shown left ventricular (LV) early diastolic LV untwisting rate is directly related to LV intra-ventricular pressure gradient (IVPG) between LV base and apex during early diastole. Recent introduction of vector flow mapping (VFM) using combination of color Doppler and speckle-tracking echocardiography provides noninvasive and feasible assessment of early diastolic IVPG shortly after aortic valve closure including isovolmic relaxation period (ED-IVPG) in humans. However, relationship between VFM–derived ED-IVPG and early diastolic LV untwisting rate has not been well investigated.
Purpose
The purpose of this study was to examine relationship between ED-IVPG estimated by VFM and LV untwisting rate by speckle-tracking echocardiography.
Methods
The study population consists of 66 patients without segmental wall motion abnormality, significant valvular diseases, and atrial fibrillation who underwent echocardiography for evaluation of LV function (age: 60±15 years, LVEF: 49±16%). From the apical long-axis views by color Doppler echocardiography, we analyzed peak ED-IVPG between LV base and apex just after aortic valve closure (figure) using commercially available VFM analysis software (DAS-RS1, Hitachi). We assessed peak early diastolic LV untwisting rate and LV torsion from LV basal and apical short-axis view by speckle-tracking echocardiography. We evaluated correlation between ED-IVPG and LV untwisting rate. We also evaluated correlation between ED-IVPG and peak systolic LV torsion, LV end-diastolic (EDV) and end-systolic volumes (ESV), ejection fraction (EF), early diastolic velocity (E) of LV inflow, average early diastolic velocity (e') of mitral annulus, and average E/e'.
Results
In all the study patients, ED-IVPG was successfully and quickly evaluated. 1) ED-IVPG correlated well with peak LV untwisting rate (r=0.64, p<0.0001). 2) ED-IVPG significantly correlated with LV torsion, LVEDV, LVESV, and LVEF (r=0.47, r=−0.48, r=−0.46, and r=0.48, respectively, p<0.001). 3) There were no significant correlations between ED-IVPG and other indexes including E, average e', and average E/e'. According to receiver operating characteristic analysis, the best cut-off value of ED-IVPG for determining impaired LV untwisting rate (<80 degrees/s) was found at 0.42 mmHg (sensitivity 81%, specificity 76%, and area under the curve 0.86)
ED-IVPG measurement by VFM
Conclusions
The present results showed that noninvasive VFM-derived peak ED-IVPG shortly after aortic valve closure is related to early diastolic peak LV untwisting rate. ED-IVPG easily and quickly estimated by VFM may be used as an additional index for LV diastolic function.
Collapse
Affiliation(s)
- T Hozumi
- Wakayama Medical University, Wakayama, Japan
| | - Y Nozawa
- Wakayama Medical University, Wakayama, Japan
| | - K Takemoto
- Wakayama Medical University, Wakayama, Japan
| | - T Nishi
- Wakayama Medical University, Wakayama, Japan
| | - T Wada
- Wakayama Medical University, Wakayama, Japan
| | - N Maniwa
- Wakayama Medical University, Wakayama, Japan
| | - K Kashiwagi
- Wakayama Medical University, Wakayama, Japan
| | - K Shimamura
- Wakayama Medical University, Wakayama, Japan
| | - A Kuroi
- Wakayama Medical University, Wakayama, Japan
| | - Y Matsuo
- Wakayama Medical University, Wakayama, Japan
| | - H Kitabata
- Wakayama Medical University, Wakayama, Japan
| | - Y Ino
- Wakayama Medical University, Wakayama, Japan
| | - T Kubo
- Wakayama Medical University, Wakayama, Japan
| | - A Tanaka
- Wakayama Medical University, Wakayama, Japan
| | - T Akasaka
- Wakayama Medical University, Wakayama, Japan
| |
Collapse
|
13
|
Nishi T, Hozumi T, Takemoto K, Wada T, Maniwa N, Kashiwagi M, Shimamura K, Shiono Y, Kuroi A, Matsuo Y, Kitabata H, Ino Y, Kubo T, Tanaka A, Akasaka T. P4349Simple and rapid estimation of left ventricular longitudinal deformation by tissue-tracking mitral annular displacement in single apical view. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0757] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Noninvasive assessment of left ventricular (LV) deformation using global longitudinal strain (GLS) has prognostic value in patients with and without preserved ejection fraction (EF). Application of speckle-tracking technology to the mitral annulus provides rapid and easy assessment of displacement of septal and lateral mitral annulus and mid-point of mitral annular line in single apical view (TMAD) even in poor echo-image quality. TMAD may be used as a simple index of LV longitudinal deformation in patients with and without preserved EF (Figure).
Purpose
The purpose of this study was to examine whether TMAD can be used as a simple index of LV longitudinal deformation in patients with and without preserved EF.
Methods
The study population consists of 95 patients without segmental wall motion abnormality, significant valvular diseases, and atrial fibrillation in whom both TMAD and GLS measurements were applied by QLAB software (Philips). We estimated GLS from apical 4- and 2-chamber views and apical longitudinal views, and TMAD from apical 4-chamber view. TMAD was automatically and quickly evaluated as the base-to-apex displacement of septal (TMADsep), lateral (TMADlat), and mid-point of annular line (TMADmid) (Figure). The percentage of M-TMAD to LV length from the mid-point of mitral annuls to the apex at end-diastole (%TMADmid) was also calculated. We compared each TMAD values with GLS values by linear regression analysis, and evluated TMAD values by a receiver operating characteristic (ROC) analysis to detect impaired LV longitudinal deformation (|GLS|<12.0%).
Results
TMAD was successfully assessed in 94 of 95 patients (99%) while GLS was measured in 84 of 95 patients (87%, p=0.0082 vs TMAD). There were good correlations between each TMAD index and |GLS| (TMADsep:r=0.77, TMADlat:r=0.81, TMADmid:r=0.82, %TMADmid:r=0.87). According to ROC curve, the best cut-off values for TMADsep, TMADlat, TMADmid, and %TMADmid in determining LV longitudinal deformation were 6.8mm, 8.0mm, 7.8mm, and 9.5% respectively (Table).
Conclusions
The present results suggest that rapid and easy assessment of TMAD in single apical view may be used as a simple index of LV longitudinal deformation.
Collapse
Affiliation(s)
- T Nishi
- Wakayama Medical University, Wakayama, Japan
| | - T Hozumi
- Wakayama Medical University, Wakayama, Japan
| | - K Takemoto
- Wakayama Medical University, Wakayama, Japan
| | - T Wada
- Wakayama Medical University, Wakayama, Japan
| | - N Maniwa
- Wakayama Medical University, Wakayama, Japan
| | - M Kashiwagi
- Wakayama Medical University, Wakayama, Japan
| | - K Shimamura
- Wakayama Medical University, Wakayama, Japan
| | - Y Shiono
- Wakayama Medical University, Wakayama, Japan
| | - A Kuroi
- Wakayama Medical University, Wakayama, Japan
| | - Y Matsuo
- Wakayama Medical University, Wakayama, Japan
| | - H Kitabata
- Wakayama Medical University, Wakayama, Japan
| | - Y Ino
- Wakayama Medical University, Wakayama, Japan
| | - T Kubo
- Wakayama Medical University, Wakayama, Japan
| | - A Tanaka
- Wakayama Medical University, Wakayama, Japan
| | - T Akasaka
- Wakayama Medical University, Wakayama, Japan
| |
Collapse
|
14
|
Li JC, Zhang HS, Zhao XY, Jiang JG, Wu YX, Lu YL, Zhang LQ, Nishi T. Development of high damping natural rubber/butyl rubber composites compatibilized by isobutylene-isoprene block copolymer for isolation bearing. EXPRESS POLYM LETT 2019. [DOI: 10.3144/expresspolymlett.2019.58] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
15
|
Derimay F, Rioufol G, Fearon W, Kobayashi Y, Nishi T, Finet G. Optimal balloon positioning to maximize the proximal optimization technique (POT). Archives of Cardiovascular Diseases Supplements 2019. [DOI: 10.1016/j.acvdsp.2018.10.043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
16
|
Wei X, Nishi T, Kondou S, Kimura H, Mody I. Preferential enhancement of GluN2B-containing native NMDA receptors by the endogenous modulator 24S-hydroxycholesterol in hippocampal neurons. Neuropharmacology 2018; 148:11-20. [PMID: 30594698 DOI: 10.1016/j.neuropharm.2018.12.028] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2018] [Revised: 12/11/2018] [Accepted: 12/26/2018] [Indexed: 11/24/2022]
Abstract
24S-hydroxycholesterol (24HC) is the major metabolic breakdown product of cholesterol in the brain. Among its other effects on neurons, 24HC modulates N-methyl-d-aspartate (NMDA or GluN) receptors, but our understanding of this mechanism is poor. We used whole-cell patch clamp recordings and various pharmacological approaches in mouse brain slices to record isolated NMDAR-mediated (INMDA) tonic and evoked synaptic currents. 24HC (1 μΜ) significantly enhanced tonic, but not evoked, INMDA of dentate gyrus granule cells. The INMDA had both GluN2A and GluN2B-mediated components. Preincubation of the slices with PEAQX (a GluN2A antagonist) or Ro25-6981 (a GluN2B antagonist) dramatically changed the INMDA modulatory potential of 24HC. Ro25-6981 blocked the enhancing effect of 24HC on tonic INMDA, while preincubation with PEAQX had no effect. In cholesterol 24-hydroxylase (CYP46A1) knockout mice, in sharp contrast to WT, 24HC slightly decreased the tonic INMDA of granule cells. Furthermore, 24HC had no effect on tonic INMDA of dentate gyrus parvalbumin interneurons (PV-INs), known to express different GluN subunits than granule cells. Taken together, our results revealed a specific enhancement of GluN2B-containing NMDARs by 24HC, indicating a novel endogenous pathway to influence a subclass of NMDARs critically involved in cortical plasticity and in numerous neurological and psychiatric disorders.
Collapse
Affiliation(s)
- Xiaofei Wei
- Department of Neurology, The David Geffen School of Medicine at UCLA, Los Angeles, CA, 90095, USA
| | - Toshiya Nishi
- Department of Physiology, The David Geffen School of Medicine at UCLA, Los Angeles, CA, 90095, USA
| | - Shinichi Kondou
- Department of Physiology, The David Geffen School of Medicine at UCLA, Los Angeles, CA, 90095, USA
| | - Haruhide Kimura
- Department of Physiology, The David Geffen School of Medicine at UCLA, Los Angeles, CA, 90095, USA
| | - Istvan Mody
- Department of Neurology, The David Geffen School of Medicine at UCLA, Los Angeles, CA, 90095, USA; Research, Takeda Pharmaceutical Company Ltd, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan.
| |
Collapse
|
17
|
Sasaki H, Nakamura H, Ono H, Yoshino S, Sakurai Y, Yoza N, Iwata T, Matsumura K, Satoh Y, Aoki N, Usuba W, Nishi T, Katsuoka Y, Nakazawa R. Routine Referral by Urologists Increase Opportunities for Corneal Donation. Transplant Proc 2018; 50:2986-2991. [PMID: 30577158 DOI: 10.1016/j.transproceed.2018.09.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2018] [Accepted: 09/05/2018] [Indexed: 11/29/2022]
Abstract
BACKGROUND The levels of corneal donation are insufficient to meet the demand for corneal transplantation in Japan. To overcome this problem, we started to routinely mention the possibility of corneal donation to the families of patients who died in our hospital's Urology Department in February 2008. In this study, we evaluated the effectiveness of this approach. METHODS We retrospectively reviewed the medical records of the patients who died in the Department of Urology, St. Marianna University School of Medicine Hospital, and analyzed the patients' characteristics and information about corneal donation. RESULTS In total, 211 patients died in our department between February 2008 and March 2017, and 155 patients were medically suitable corneal donors. We mentioned the possibility of corneal donation to 129 (83.2%) families, and 29 (18.7%) families agreed. Three families subsequently withdrew their consent. Finally, 26 (16.8%) of the families that were approached about corneal donation by urologists agreed to donate their relatives' corneas. Another 2 families voluntarily offered to donate their relatives' corneas. Thus, 28 (18.1%) of 155 medically suitable donors donated their corneas for transplantation. Twenty-six (92.8%) donors were 60 years or older and all donors were affected with malignant genitourinary tumors. Fifty-four (96.4%) corneas were successfully transplanted into recipients. CONCLUSIONS Even elderly patients who die of solid carcinoma can be an important source of corneal donors. In this study, we showed that routine referral by urologists increased corneal donation. If this approach were adopted by other departments, it might further increase the number of corneal donations.
Collapse
Affiliation(s)
- H Sasaki
- Department of Urology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
| | - H Nakamura
- Transplant Support Service, St. Marianna University Hospital, Kawasaki, Kanagawa, Japan
| | - H Ono
- Transplant Support Service, St. Marianna University Hospital, Kawasaki, Kanagawa, Japan
| | - S Yoshino
- Transplant Support Service, St. Marianna University Hospital, Kawasaki, Kanagawa, Japan
| | - Y Sakurai
- Transplant Support Service, St. Marianna University Hospital, Kawasaki, Kanagawa, Japan
| | - N Yoza
- Department of Urology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
| | - T Iwata
- Department of Urology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
| | - K Matsumura
- Department of Urology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
| | - Y Satoh
- Department of Urology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
| | - N Aoki
- Department of Urology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
| | - W Usuba
- Department of Urology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
| | - T Nishi
- Department of Urology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
| | - Y Katsuoka
- Department of Urology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
| | - R Nakazawa
- Department of Urology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
| |
Collapse
|
18
|
Nishi T, Itahashi K, Berg GPA, Fujioka H, Fukuda N, Fukunishi N, Geissel H, Hayano RS, Hirenzaki S, Ichikawa K, Ikeno N, Inabe N, Itoh S, Iwasaki M, Kameda D, Kawase S, Kubo T, Kusaka K, Matsubara H, Michimasa S, Miki K, Mishima G, Miya H, Nagahiro H, Nakamura M, Noji S, Okochi K, Ota S, Sakamoto N, Suzuki K, Takeda H, Tanaka YK, Todoroki K, Tsukada K, Uesaka T, Watanabe YN, Weick H, Yamakami H, Yoshida K. Spectroscopy of Pionic Atoms in ^{122}Sn(d,^{3}He) Reaction and Angular Dependence of the Formation Cross Sections. Phys Rev Lett 2018; 120:152505. [PMID: 29756883 DOI: 10.1103/physrevlett.120.152505] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/24/2017] [Revised: 02/07/2018] [Indexed: 06/08/2023]
Abstract
We observed the atomic 1s and 2p states of π^{-} bound to ^{121}Sn nuclei as distinct peak structures in the missing mass spectra of the ^{122}Sn(d,^{3}He) nuclear reaction. A very intense deuteron beam and a spectrometer with a large angular acceptance let us achieve a potential of discovery, which includes the capability of determining the angle-dependent cross sections with high statistics. The 2p state in a Sn nucleus was observed for the first time. The binding energies and widths of the pionic states are determined and found to be consistent with previous experimental results of other Sn isotopes. The spectrum is measured at finite reaction angles for the first time. The formation cross sections at the reaction angles between 0° and 2° are determined. The observed reaction-angle dependence of each state is reproduced by theoretical calculations. However, the quantitative comparison with our high-precision data reveals a significant discrepancy between the measured and calculated formation cross sections of the pionic 1s state.
Collapse
Affiliation(s)
- T Nishi
- Department of Physics, School of Science, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, 113-0033 Tokyo, Japan
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - K Itahashi
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - G P A Berg
- Department of Physics and the Joint Institute for Nuclear Astrophysics Center for the Evolution of the Elements, University of Notre Dame, Notre Dame, Indiana 46556, USA
| | - H Fujioka
- Department of Physics, Kyoto University, Kitashirakawa-Oiwakecho, Sakyo-ku, Kyoto, 606-8502 Kyoto, Japan
| | - N Fukuda
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - N Fukunishi
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - H Geissel
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Planckstrasse 1, D-64291 Darmstadt, Germany
| | - R S Hayano
- Department of Physics, School of Science, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, 113-0033 Tokyo, Japan
| | - S Hirenzaki
- Department of Physics, Nara Women's University, Kita-Uoya Nishimachi, Nara, 630-8506 Nara, Japan
| | - K Ichikawa
- Department of Physics, School of Science, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, 113-0033 Tokyo, Japan
| | - N Ikeno
- Department of Life and Environmental Agricultural Sciences, Faculty of Agriculture, Tottori University, 4-101 Koyamacho-Minami, Tottori, 680-8551 Tottori, Japan
| | - N Inabe
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - S Itoh
- Department of Physics, School of Science, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, 113-0033 Tokyo, Japan
| | - M Iwasaki
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - D Kameda
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - S Kawase
- Center for Nuclear Study, The University of Tokyo, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - T Kubo
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - K Kusaka
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - H Matsubara
- Center for Nuclear Study, The University of Tokyo, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - S Michimasa
- Center for Nuclear Study, The University of Tokyo, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - K Miki
- Department of Physics, School of Science, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, 113-0033 Tokyo, Japan
| | - G Mishima
- Department of Physics, School of Science, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, 113-0033 Tokyo, Japan
| | - H Miya
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - H Nagahiro
- Department of Physics, Nara Women's University, Kita-Uoya Nishimachi, Nara, 630-8506 Nara, Japan
| | - M Nakamura
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - S Noji
- Department of Physics, School of Science, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, 113-0033 Tokyo, Japan
| | - K Okochi
- Department of Physics, School of Science, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, 113-0033 Tokyo, Japan
| | - S Ota
- Center for Nuclear Study, The University of Tokyo, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - N Sakamoto
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - K Suzuki
- Stefan Meyer Institute for Subatomic Physics, Austrian Academy of Sciences, Boltzmanngasse 3, A-1090 Vienna, Austria
| | - H Takeda
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - Y K Tanaka
- Department of Physics, School of Science, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, 113-0033 Tokyo, Japan
| | - K Todoroki
- Department of Physics, School of Science, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, 113-0033 Tokyo, Japan
| | - K Tsukada
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - T Uesaka
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - Y N Watanabe
- Department of Physics, School of Science, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, 113-0033 Tokyo, Japan
| | - H Weick
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Planckstrasse 1, D-64291 Darmstadt, Germany
| | - H Yamakami
- Department of Physics, Kyoto University, Kitashirakawa-Oiwakecho, Sakyo-ku, Kyoto, 606-8502 Kyoto, Japan
| | - K Yoshida
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| |
Collapse
|
19
|
Inagaki M, Ota D, Tsuji M, Nishi T, Kato T, Kobayashi Y, Mori M, Fukuuchi A. T2-weighted magnetic resonance images of triple negative breast cancer with high tumor infiltrating lymphocytes. Breast 2017. [DOI: 10.1016/s0960-9776(17)30193-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
20
|
Tanaka YK, Itahashi K, Fujioka H, Ayyad Y, Benlliure J, Brinkmann KT, Friedrich S, Geissel H, Gellanki J, Guo C, Gutz E, Haettner E, Harakeh MN, Hayano RS, Higashi Y, Hirenzaki S, Hornung C, Igarashi Y, Ikeno N, Iwasaki M, Jido D, Kalantar-Nayestanaki N, Kanungo R, Knöbel R, Kurz N, Metag V, Mukha I, Nagae T, Nagahiro H, Nanova M, Nishi T, Ong HJ, Pietri S, Prochazka A, Rappold C, Reiter MP, Rodríguez-Sánchez JL, Scheidenberger C, Simon H, Sitar B, Strmen P, Sun B, Suzuki K, Szarka I, Takechi M, Tanihata I, Terashima S, Watanabe YN, Weick H, Widmann E, Winfield JS, Xu X, Yamakami H, Zhao J. Measurement of Excitation Spectra in the ^{12}C(p,d) Reaction near the η^{'} Emission Threshold. Phys Rev Lett 2016; 117:202501. [PMID: 27886506 DOI: 10.1103/physrevlett.117.202501] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/11/2016] [Indexed: 06/06/2023]
Abstract
Excitation spectra of ^{11}C are measured in the ^{12}C(p,d) reaction near the η^{'} emission threshold. A proton beam extracted from the synchrotron SIS-18 at GSI with an incident energy of 2.5 GeV impinges on a carbon target. The momenta of deuterons emitted at 0° are precisely measured with the fragment separator (FRS) operated as a spectrometer. In contrast to theoretical predictions on the possible existence of deeply bound η^{'}-mesic states in carbon nuclei, no distinct structures are observed associated with the formation of bound states. The spectra are analyzed to set stringent constraints on the formation cross section and on the hitherto barely known η^{'}-nucleus interaction.
Collapse
Affiliation(s)
- Y K Tanaka
- The University of Tokyo, 7-3-1 Hongo, Bunkyo, 113-0033 Tokyo, Japan
| | - K Itahashi
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - H Fujioka
- Kyoto University, Kitashirakawa-Oiwakecho, Sakyo-ku, 606-8502 Kyoto, Japan
| | - Y Ayyad
- RCNP, Osaka University, 10-1 Mihogaoka, Ibaraki, 567-0047 Osaka, Japan
| | - J Benlliure
- Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - K-T Brinkmann
- Universität Giessen, Heinrich-Buff-Ring 16, 35392 Giessen, Germany
| | - S Friedrich
- Universität Giessen, Heinrich-Buff-Ring 16, 35392 Giessen, Germany
| | - H Geissel
- Universität Giessen, Heinrich-Buff-Ring 16, 35392 Giessen, Germany
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Planckstraße 1, 64291 Darmstadt, Germany
| | - J Gellanki
- KVI-CART, University of Groningen, Zernikelaan 25, 9747 AA Groningen, The Netherlands
| | - C Guo
- Beihang University, Xueyuan Road 37, Haidian District, 100191 Beijing, China
| | - E Gutz
- Universität Giessen, Heinrich-Buff-Ring 16, 35392 Giessen, Germany
| | - E Haettner
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Planckstraße 1, 64291 Darmstadt, Germany
| | - M N Harakeh
- KVI-CART, University of Groningen, Zernikelaan 25, 9747 AA Groningen, The Netherlands
| | - R S Hayano
- The University of Tokyo, 7-3-1 Hongo, Bunkyo, 113-0033 Tokyo, Japan
| | - Y Higashi
- Nara Women's University, Kita-Uoya Nishi-Machi, 630-8506 Nara, Japan
| | - S Hirenzaki
- Nara Women's University, Kita-Uoya Nishi-Machi, 630-8506 Nara, Japan
| | - C Hornung
- Universität Giessen, Heinrich-Buff-Ring 16, 35392 Giessen, Germany
| | - Y Igarashi
- KEK, 1-1 Oho, Tsukuba, 305-0801 Ibaraki, Japan
| | - N Ikeno
- Tottori University, 4-101 Koyamacho-minami, 680-8551 Tottori, Japan
| | - M Iwasaki
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - D Jido
- Tokyo Metropolitan University, 1-1 Minami-Osawa, Hachioji, 192-0397 Tokyo, Japan
| | | | - R Kanungo
- Saint Mary's University, 923 Robie Street, Halifax, Nova Scotia B3H 3C3, Canada
| | - R Knöbel
- Universität Giessen, Heinrich-Buff-Ring 16, 35392 Giessen, Germany
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Planckstraße 1, 64291 Darmstadt, Germany
| | - N Kurz
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Planckstraße 1, 64291 Darmstadt, Germany
| | - V Metag
- Universität Giessen, Heinrich-Buff-Ring 16, 35392 Giessen, Germany
| | - I Mukha
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Planckstraße 1, 64291 Darmstadt, Germany
| | - T Nagae
- Kyoto University, Kitashirakawa-Oiwakecho, Sakyo-ku, 606-8502 Kyoto, Japan
| | - H Nagahiro
- Nara Women's University, Kita-Uoya Nishi-Machi, 630-8506 Nara, Japan
| | - M Nanova
- Universität Giessen, Heinrich-Buff-Ring 16, 35392 Giessen, Germany
| | - T Nishi
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - H J Ong
- RCNP, Osaka University, 10-1 Mihogaoka, Ibaraki, 567-0047 Osaka, Japan
| | - S Pietri
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Planckstraße 1, 64291 Darmstadt, Germany
| | - A Prochazka
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Planckstraße 1, 64291 Darmstadt, Germany
| | - C Rappold
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Planckstraße 1, 64291 Darmstadt, Germany
| | - M P Reiter
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Planckstraße 1, 64291 Darmstadt, Germany
| | | | - C Scheidenberger
- Universität Giessen, Heinrich-Buff-Ring 16, 35392 Giessen, Germany
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Planckstraße 1, 64291 Darmstadt, Germany
| | - H Simon
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Planckstraße 1, 64291 Darmstadt, Germany
| | - B Sitar
- Comenius University Bratislava, Mlynská dolina, 842 48 Bratislava, Slovakia
| | - P Strmen
- Comenius University Bratislava, Mlynská dolina, 842 48 Bratislava, Slovakia
| | - B Sun
- Beihang University, Xueyuan Road 37, Haidian District, 100191 Beijing, China
| | - K Suzuki
- Stefan-Meyer-Institut für subatomare Physik, Boltzmangasse 3, 1090 Vienna, Austria
| | - I Szarka
- Comenius University Bratislava, Mlynská dolina, 842 48 Bratislava, Slovakia
| | - M Takechi
- Niigata University, 8050 Ikarashi 2-no-cho, Nishi-ku, 950-2181 Niigata, Japan
| | - I Tanihata
- RCNP, Osaka University, 10-1 Mihogaoka, Ibaraki, 567-0047 Osaka, Japan
- Beihang University, Xueyuan Road 37, Haidian District, 100191 Beijing, China
| | - S Terashima
- Beihang University, Xueyuan Road 37, Haidian District, 100191 Beijing, China
| | - Y N Watanabe
- The University of Tokyo, 7-3-1 Hongo, Bunkyo, 113-0033 Tokyo, Japan
| | - H Weick
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Planckstraße 1, 64291 Darmstadt, Germany
| | - E Widmann
- Stefan-Meyer-Institut für subatomare Physik, Boltzmangasse 3, 1090 Vienna, Austria
| | - J S Winfield
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Planckstraße 1, 64291 Darmstadt, Germany
| | - X Xu
- Universität Giessen, Heinrich-Buff-Ring 16, 35392 Giessen, Germany
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Planckstraße 1, 64291 Darmstadt, Germany
| | - H Yamakami
- Kyoto University, Kitashirakawa-Oiwakecho, Sakyo-ku, 606-8502 Kyoto, Japan
| | - J Zhao
- Beihang University, Xueyuan Road 37, Haidian District, 100191 Beijing, China
| |
Collapse
|
21
|
Mori Y, Nishimura Y, Hanayama R, Nakayama S, Ishii K, Kitagawa Y, Sekine T, Sato N, Kurita T, Kawashima T, Kan H, Komeda O, Nishi T, Azuma H, Hioki T, Motohiro T, Sunahara A, Sentoku Y, Miura E. Fast Heating of Imploded Core with Counterbeam Configuration. Phys Rev Lett 2016; 117:055001. [PMID: 27517775 DOI: 10.1103/physrevlett.117.055001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/08/2016] [Indexed: 06/06/2023]
Abstract
A tailored-pulse-imploded core with a diameter of 70 μm is flashed by counterirradiating 110 fs, 7 TW laser pulses. Photon emission (>40 eV) from the core exceeds the emission from the imploded core by 6 times, even though the heating pulse energies are only one seventh of the implosion energy. The coupling efficiency from the heating laser to the core using counterirradiation is 14% from the enhancement of photon emission. Neutrons are also produced by counterpropagating fast deuterons accelerated by the photon pressure of the heating pulses. A collisional two-dimensional particle-in-cell simulation reveals that the collisionless two counterpropagating fast-electron currents induce mega-Gauss magnetic filaments in the center of the core due to the Weibel instability. The counterpropagating fast-electron currents are absolutely unstable and independent of the core density and resistivity. Fast electrons with energy below a few MeV are trapped by these filaments in the core region, inducing an additional coupling. This might lead to the observed bright photon emissions.
Collapse
Affiliation(s)
- Y Mori
- The Graduate School for the Creation of New Photonics Industries, 1955-1 Kurematsuchou, Nishi-ku, Hamamatsu 431-1202, Japan
| | - Y Nishimura
- The Graduate School for the Creation of New Photonics Industries, 1955-1 Kurematsuchou, Nishi-ku, Hamamatsu 431-1202, Japan
| | - R Hanayama
- The Graduate School for the Creation of New Photonics Industries, 1955-1 Kurematsuchou, Nishi-ku, Hamamatsu 431-1202, Japan
| | - S Nakayama
- The Graduate School for the Creation of New Photonics Industries, 1955-1 Kurematsuchou, Nishi-ku, Hamamatsu 431-1202, Japan
| | - K Ishii
- The Graduate School for the Creation of New Photonics Industries, 1955-1 Kurematsuchou, Nishi-ku, Hamamatsu 431-1202, Japan
| | - Y Kitagawa
- The Graduate School for the Creation of New Photonics Industries, 1955-1 Kurematsuchou, Nishi-ku, Hamamatsu 431-1202, Japan
| | - T Sekine
- Hamamatsu Photonics, K. K. 1820 Kurematsuchou, Nishi-ku, Hamamatsu 431-1202, Japan
| | - N Sato
- Hamamatsu Photonics, K. K. 1820 Kurematsuchou, Nishi-ku, Hamamatsu 431-1202, Japan
| | - T Kurita
- Hamamatsu Photonics, K. K. 1820 Kurematsuchou, Nishi-ku, Hamamatsu 431-1202, Japan
| | - T Kawashima
- Hamamatsu Photonics, K. K. 1820 Kurematsuchou, Nishi-ku, Hamamatsu 431-1202, Japan
| | - H Kan
- Hamamatsu Photonics, K. K. 1820 Kurematsuchou, Nishi-ku, Hamamatsu 431-1202, Japan
| | - O Komeda
- Advanced Material Engineering Division, Toyota Motor Corporation, 1200 Mishuku, Susono, Shizuoka 410-1193, Japan
| | - T Nishi
- Toyota Central Research and Development Laboratories, Inc., 41-1 Yokomichi, Nagakute, Aichi 480-1192, Japan
| | - H Azuma
- Aichi Synchrotron Radiation Center, Minamiyamaguchi-cho, Seto-shi, Aichi-ken 489-0965, Japan
| | - T Hioki
- Green Mobility Collaborative Research Center, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8601, Japan
| | - T Motohiro
- Green Mobility Collaborative Research Center, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8601, Japan
| | - A Sunahara
- Institute for Laser Technology, 1-8-4 Utsubo-honmachi, Nishi-ku, Osaka 550-0004, Japan
| | - Y Sentoku
- Department of Physics, University of Nevada, Reno, 1664 North Virginia Street, Reno, Nevada 89557, USA
| | - E Miura
- National Institute of Advanced Industrial Science and Technology, 1-1-1 Umezono, Tsukuba, Ibaraki 305-8568, Japan
| |
Collapse
|
22
|
Nakayama T, Yasojima H, Morimoto T, Yoshidome K, Mizutani M, Takashima T, Matsunami N, Enami A, Kagawa M, Nomura T, Shiba E, Nishi T, Kamigaki S, Kozuma Y, Yoshinami T, Masuda N. Abstract P1-10-26: Frozen glove could be a new hope for prevention of chemotherapy induced peripheral neuropathy. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p1-10-26] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction
Chemotherapy induced peripheral neuropathy (CIPN) is a major problem for patients who receive chemotherapy, and it sometimes deteriorate patients' QOL. Many CIPN prevention trials have been conducted, but no one succeeded to date.
Objectives
To investigate if frozen glove (FG) prevents peripheral neuropathy induced by nanoparticle albumin-bound paclitaxel (nab-PTX).
Methods
We conducted CIPN prevention study using FG, as part of multi-institutional phase II study which analyze efficacy and safety of nab-PTX (260mg/m2 q3w) followed by FEC (500/100/500 mg/m2, q3w) in pre-operative setting (KBCSG-TR 1213 trial). Each patient wore an FGs for a total of 60 minutes (15mins before and after nab-PTX treatment) on both hands. CIPN were assessed during treatment period with nab-PTX by the Patient Neurotoxicity Questionnaire (PNQ) and the FACT/GOG (Gynecologic Oncology Group) Neurotoxicity (Ntx) subscale. Patients were asked to access PNQ and FACT/GOG Ntx on a daily basis and recorded in the CIPN diary.
Results
Sixty two patients were registered for KBCSG-TR 1213 trial. And forty two pts (68%) who turned in the diary were analyzed. Median age and median body mass index (BMI) was 48 years old and 21.6 kg/m2, respectively. We analyzed following 6 categories, 1) symptoms of hands and arms, 2) symptoms of foots, 3) symptoms of general, 4) symptoms of ears 5) muscle weakness of hands and arms and 6) muscle weakness of foots. Median time to each event was 1) 25.5 days, 2) 5days, 3) 3days, 4) not available, 5) 46.5days, 6)4 days. By using FG, time to event of hands and arms was much longer compared with that of foots.
Conclusions
CIPN could be prevented or lessened by FG. Randomized phase II CIPN prevention study has been just launched.
Citation Format: Nakayama T, Yasojima H, Morimoto T, Yoshidome K, Mizutani M, Takashima T, Matsunami N, Enami A, Kagawa M, Nomura T, Shiba E, Nishi T, Kamigaki S, Kozuma Y, Yoshinami T, Masuda N. Frozen glove could be a new hope for prevention of chemotherapy induced peripheral neuropathy. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-10-26.
Collapse
Affiliation(s)
- T Nakayama
- Osaka Medical Center for Cancer and Cardiovascular Disease, Osaka, Japan; NHO Osaka National Hospital, Osaka, Japan; Yao Municipal Hospital, Yao, Osaka, Japan; Osaka Police Hospital, Osaka, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; Osaka Rosai Hospital, Sakai, Osaka, Japan; Osaka Breast Clinic, Osaka, Japan; Kaizuka City Hospital, Kaizuka, Osaka, Japan; Sakai City Hospital, Sakai, Osaka, Japan; Higashiosaka City Genaral Hospital, Higashiosaka, Osaka, Japan
| | - H Yasojima
- Osaka Medical Center for Cancer and Cardiovascular Disease, Osaka, Japan; NHO Osaka National Hospital, Osaka, Japan; Yao Municipal Hospital, Yao, Osaka, Japan; Osaka Police Hospital, Osaka, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; Osaka Rosai Hospital, Sakai, Osaka, Japan; Osaka Breast Clinic, Osaka, Japan; Kaizuka City Hospital, Kaizuka, Osaka, Japan; Sakai City Hospital, Sakai, Osaka, Japan; Higashiosaka City Genaral Hospital, Higashiosaka, Osaka, Japan
| | - T Morimoto
- Osaka Medical Center for Cancer and Cardiovascular Disease, Osaka, Japan; NHO Osaka National Hospital, Osaka, Japan; Yao Municipal Hospital, Yao, Osaka, Japan; Osaka Police Hospital, Osaka, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; Osaka Rosai Hospital, Sakai, Osaka, Japan; Osaka Breast Clinic, Osaka, Japan; Kaizuka City Hospital, Kaizuka, Osaka, Japan; Sakai City Hospital, Sakai, Osaka, Japan; Higashiosaka City Genaral Hospital, Higashiosaka, Osaka, Japan
| | - K Yoshidome
- Osaka Medical Center for Cancer and Cardiovascular Disease, Osaka, Japan; NHO Osaka National Hospital, Osaka, Japan; Yao Municipal Hospital, Yao, Osaka, Japan; Osaka Police Hospital, Osaka, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; Osaka Rosai Hospital, Sakai, Osaka, Japan; Osaka Breast Clinic, Osaka, Japan; Kaizuka City Hospital, Kaizuka, Osaka, Japan; Sakai City Hospital, Sakai, Osaka, Japan; Higashiosaka City Genaral Hospital, Higashiosaka, Osaka, Japan
| | - M Mizutani
- Osaka Medical Center for Cancer and Cardiovascular Disease, Osaka, Japan; NHO Osaka National Hospital, Osaka, Japan; Yao Municipal Hospital, Yao, Osaka, Japan; Osaka Police Hospital, Osaka, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; Osaka Rosai Hospital, Sakai, Osaka, Japan; Osaka Breast Clinic, Osaka, Japan; Kaizuka City Hospital, Kaizuka, Osaka, Japan; Sakai City Hospital, Sakai, Osaka, Japan; Higashiosaka City Genaral Hospital, Higashiosaka, Osaka, Japan
| | - T Takashima
- Osaka Medical Center for Cancer and Cardiovascular Disease, Osaka, Japan; NHO Osaka National Hospital, Osaka, Japan; Yao Municipal Hospital, Yao, Osaka, Japan; Osaka Police Hospital, Osaka, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; Osaka Rosai Hospital, Sakai, Osaka, Japan; Osaka Breast Clinic, Osaka, Japan; Kaizuka City Hospital, Kaizuka, Osaka, Japan; Sakai City Hospital, Sakai, Osaka, Japan; Higashiosaka City Genaral Hospital, Higashiosaka, Osaka, Japan
| | - N Matsunami
- Osaka Medical Center for Cancer and Cardiovascular Disease, Osaka, Japan; NHO Osaka National Hospital, Osaka, Japan; Yao Municipal Hospital, Yao, Osaka, Japan; Osaka Police Hospital, Osaka, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; Osaka Rosai Hospital, Sakai, Osaka, Japan; Osaka Breast Clinic, Osaka, Japan; Kaizuka City Hospital, Kaizuka, Osaka, Japan; Sakai City Hospital, Sakai, Osaka, Japan; Higashiosaka City Genaral Hospital, Higashiosaka, Osaka, Japan
| | - A Enami
- Osaka Medical Center for Cancer and Cardiovascular Disease, Osaka, Japan; NHO Osaka National Hospital, Osaka, Japan; Yao Municipal Hospital, Yao, Osaka, Japan; Osaka Police Hospital, Osaka, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; Osaka Rosai Hospital, Sakai, Osaka, Japan; Osaka Breast Clinic, Osaka, Japan; Kaizuka City Hospital, Kaizuka, Osaka, Japan; Sakai City Hospital, Sakai, Osaka, Japan; Higashiosaka City Genaral Hospital, Higashiosaka, Osaka, Japan
| | - M Kagawa
- Osaka Medical Center for Cancer and Cardiovascular Disease, Osaka, Japan; NHO Osaka National Hospital, Osaka, Japan; Yao Municipal Hospital, Yao, Osaka, Japan; Osaka Police Hospital, Osaka, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; Osaka Rosai Hospital, Sakai, Osaka, Japan; Osaka Breast Clinic, Osaka, Japan; Kaizuka City Hospital, Kaizuka, Osaka, Japan; Sakai City Hospital, Sakai, Osaka, Japan; Higashiosaka City Genaral Hospital, Higashiosaka, Osaka, Japan
| | - T Nomura
- Osaka Medical Center for Cancer and Cardiovascular Disease, Osaka, Japan; NHO Osaka National Hospital, Osaka, Japan; Yao Municipal Hospital, Yao, Osaka, Japan; Osaka Police Hospital, Osaka, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; Osaka Rosai Hospital, Sakai, Osaka, Japan; Osaka Breast Clinic, Osaka, Japan; Kaizuka City Hospital, Kaizuka, Osaka, Japan; Sakai City Hospital, Sakai, Osaka, Japan; Higashiosaka City Genaral Hospital, Higashiosaka, Osaka, Japan
| | - E Shiba
- Osaka Medical Center for Cancer and Cardiovascular Disease, Osaka, Japan; NHO Osaka National Hospital, Osaka, Japan; Yao Municipal Hospital, Yao, Osaka, Japan; Osaka Police Hospital, Osaka, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; Osaka Rosai Hospital, Sakai, Osaka, Japan; Osaka Breast Clinic, Osaka, Japan; Kaizuka City Hospital, Kaizuka, Osaka, Japan; Sakai City Hospital, Sakai, Osaka, Japan; Higashiosaka City Genaral Hospital, Higashiosaka, Osaka, Japan
| | - T Nishi
- Osaka Medical Center for Cancer and Cardiovascular Disease, Osaka, Japan; NHO Osaka National Hospital, Osaka, Japan; Yao Municipal Hospital, Yao, Osaka, Japan; Osaka Police Hospital, Osaka, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; Osaka Rosai Hospital, Sakai, Osaka, Japan; Osaka Breast Clinic, Osaka, Japan; Kaizuka City Hospital, Kaizuka, Osaka, Japan; Sakai City Hospital, Sakai, Osaka, Japan; Higashiosaka City Genaral Hospital, Higashiosaka, Osaka, Japan
| | - S Kamigaki
- Osaka Medical Center for Cancer and Cardiovascular Disease, Osaka, Japan; NHO Osaka National Hospital, Osaka, Japan; Yao Municipal Hospital, Yao, Osaka, Japan; Osaka Police Hospital, Osaka, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; Osaka Rosai Hospital, Sakai, Osaka, Japan; Osaka Breast Clinic, Osaka, Japan; Kaizuka City Hospital, Kaizuka, Osaka, Japan; Sakai City Hospital, Sakai, Osaka, Japan; Higashiosaka City Genaral Hospital, Higashiosaka, Osaka, Japan
| | - Y Kozuma
- Osaka Medical Center for Cancer and Cardiovascular Disease, Osaka, Japan; NHO Osaka National Hospital, Osaka, Japan; Yao Municipal Hospital, Yao, Osaka, Japan; Osaka Police Hospital, Osaka, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; Osaka Rosai Hospital, Sakai, Osaka, Japan; Osaka Breast Clinic, Osaka, Japan; Kaizuka City Hospital, Kaizuka, Osaka, Japan; Sakai City Hospital, Sakai, Osaka, Japan; Higashiosaka City Genaral Hospital, Higashiosaka, Osaka, Japan
| | - T Yoshinami
- Osaka Medical Center for Cancer and Cardiovascular Disease, Osaka, Japan; NHO Osaka National Hospital, Osaka, Japan; Yao Municipal Hospital, Yao, Osaka, Japan; Osaka Police Hospital, Osaka, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; Osaka Rosai Hospital, Sakai, Osaka, Japan; Osaka Breast Clinic, Osaka, Japan; Kaizuka City Hospital, Kaizuka, Osaka, Japan; Sakai City Hospital, Sakai, Osaka, Japan; Higashiosaka City Genaral Hospital, Higashiosaka, Osaka, Japan
| | - N Masuda
- Osaka Medical Center for Cancer and Cardiovascular Disease, Osaka, Japan; NHO Osaka National Hospital, Osaka, Japan; Yao Municipal Hospital, Yao, Osaka, Japan; Osaka Police Hospital, Osaka, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; Osaka Rosai Hospital, Sakai, Osaka, Japan; Osaka Breast Clinic, Osaka, Japan; Kaizuka City Hospital, Kaizuka, Osaka, Japan; Sakai City Hospital, Sakai, Osaka, Japan; Higashiosaka City Genaral Hospital, Higashiosaka, Osaka, Japan
| |
Collapse
|
23
|
Kisamori K, Shimoura S, Miya H, Michimasa S, Ota S, Assie M, Baba H, Baba T, Beaumel D, Dozono M, Fujii T, Fukuda N, Go S, Hammache F, Ideguchi E, Inabe N, Itoh M, Kameda D, Kawase S, Kawabata T, Kobayashi M, Kondo Y, Kubo T, Kubota Y, Kurata-Nishimura M, Lee CS, Maeda Y, Matsubara H, Miki K, Nishi T, Noji S, Sakaguchi S, Sakai H, Sasamoto Y, Sasano M, Sato H, Shimizu Y, Stolz A, Suzuki H, Takaki M, Takeda H, Takeuchi S, Tamii A, Tang L, Tokieda H, Tsumura M, Uesaka T, Yako K, Yanagisawa Y, Yokoyama R, Yoshida K. Candidate Resonant Tetraneutron State Populated by the ^{4}He(^{8}He,^{8}Be) Reaction. Phys Rev Lett 2016; 116:052501. [PMID: 26894705 DOI: 10.1103/physrevlett.116.052501] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/30/2015] [Indexed: 06/05/2023]
Abstract
A candidate resonant tetraneutron state is found in the missing-mass spectrum obtained in the double-charge-exchange reaction ^{4}He(^{8}He,^{8}Be) at 186 MeV/u. The energy of the state is 0.83±0.65(stat)±1.25(syst) MeV above the threshold of four-neutron decay with a significance level of 4.9σ. Utilizing the large positive Q value of the (^{8}He,^{8}Be) reaction, an almost recoilless condition of the four-neutron system was achieved so as to obtain a weakly interacting four-neutron system efficiently.
Collapse
Affiliation(s)
- K Kisamori
- Center for Nuclear Study, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - S Shimoura
- Center for Nuclear Study, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - H Miya
- Center for Nuclear Study, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - S Michimasa
- Center for Nuclear Study, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - S Ota
- Center for Nuclear Study, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - M Assie
- IPN Orsay, 15 Rue, Georges, Clemenceau 91400 Orsay, France
| | - H Baba
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - T Baba
- Department of Physics, Kyoto University, Yoshida-Honcho, Sakyo, Kyoto 606-8501, Japan
| | - D Beaumel
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- IPN Orsay, 15 Rue, Georges, Clemenceau 91400 Orsay, France
| | - M Dozono
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - T Fujii
- Center for Nuclear Study, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - N Fukuda
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - S Go
- Center for Nuclear Study, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - F Hammache
- IPN Orsay, 15 Rue, Georges, Clemenceau 91400 Orsay, France
| | - E Ideguchi
- Research Center for Nuclear Physics, Osaka University, 10-1 Mihogaoka, Ibaraki, Osaka 567-0047, Japan
| | - N Inabe
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - M Itoh
- Cyclotron and Radioisotope Center, Tohoku University, 6-3 Aoba, Aramaki, Aoba-ku, Sendai, Miyagi 980-8578, Japan
| | - D Kameda
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - S Kawase
- Center for Nuclear Study, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - T Kawabata
- Department of Physics, Kyoto University, Yoshida-Honcho, Sakyo, Kyoto 606-8501, Japan
| | - M Kobayashi
- Center for Nuclear Study, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - Y Kondo
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8550, Japan
| | - T Kubo
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - Y Kubota
- Center for Nuclear Study, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | | | - C S Lee
- Center for Nuclear Study, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - Y Maeda
- Faculty of Engineering, University of Miyazaki, 1-1 Gakuen, Kibanadai-nishi, Miyazaki 889-2192, Japan
| | - H Matsubara
- National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage, Chiba, Japan
| | - K Miki
- Research Center for Nuclear Physics, Osaka University, 10-1 Mihogaoka, Ibaraki, Osaka 567-0047, Japan
| | - T Nishi
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Department of Physics, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - S Noji
- National Superconducting Cyclotron Laboratory, Michigan State University, 640 S Shaw Lane, East Lansing, Michigan 48824, USA
| | - S Sakaguchi
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Department of Physics, Kyushu University, 6-10-1 Hakozaki, Higashi, Fukuoka 812-8581, Japan
| | - H Sakai
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - Y Sasamoto
- Center for Nuclear Study, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - M Sasano
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - H Sato
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - Y Shimizu
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - A Stolz
- National Superconducting Cyclotron Laboratory, Michigan State University, 640 S Shaw Lane, East Lansing, Michigan 48824, USA
| | - H Suzuki
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - M Takaki
- Center for Nuclear Study, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - H Takeda
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - S Takeuchi
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - A Tamii
- Research Center for Nuclear Physics, Osaka University, 10-1 Mihogaoka, Ibaraki, Osaka 567-0047, Japan
| | - L Tang
- Center for Nuclear Study, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - H Tokieda
- Center for Nuclear Study, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - M Tsumura
- Department of Physics, Kyoto University, Yoshida-Honcho, Sakyo, Kyoto 606-8501, Japan
| | - T Uesaka
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - K Yako
- Center for Nuclear Study, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - Y Yanagisawa
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - R Yokoyama
- Center for Nuclear Study, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - K Yoshida
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| |
Collapse
|
24
|
Ogura Y, Yuki N, Sukegane A, Nishi T, Miyake Y, Sato H, Miyamoto C, Mihara C. Treatment of pressure ulcers in patients with declining renal function using arginine, glutamine and ß-hydroxy-ß-methylbutyrate. J Wound Care 2016; 24:478-82. [PMID: 26488739 DOI: 10.12968/jowc.2015.24.10.478] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
The aim of this study is to examine the efficacy on healing pressure ulcers (PU) of using a supplement combination containing arginine, glutamine and ß-hydroxy-ß-methylbutyrate, which was given to two elderly patients with renal dysfunction. The PU was surgically opened, decompressed and treated by drugs. A half quantity of the defined dose of the supplement combination, with an enteral nutrition product, was administered to the patients twice a day. This combination improved the PUs, with no effect on renal function. This novel finding may provide a nutritional rationale of arginine, glutamine and ß-hydroxy-ß-methylbutyrate for PUs associated with renal dysfunction.
Collapse
Affiliation(s)
- Y Ogura
- Assistant Professor, Professor, Department of Nutritional Sciences Faculty of Human Ecology, Yasuda Women's University, Hiroshima, Japan
| | - N Yuki
- Certified Nutrition Support Team Dietitian of JSPEN, Registered Dietitian, Department of Nutrition, Hibino Hospital, Hiroshima, Japan
| | - A Sukegane
- Certified Nutrition Support Team Occupational Therapist of JSPEN, Department of Rehabilitation, Hibino Hospital, Hiroshima, Japan
| | - T Nishi
- Pharmacist, Certified Nutrition Support Team Nurse, Department of Nursing, Hibino Hospital, Hiroshima, Japan
| | - Y Miyake
- Department of Pharmacy, Hibino Hospital, Hiroshima, Japan
| | - H Sato
- Department of Neurosurgery, Hibino Hospital, Hiroshima, Japan
| | - C Miyamoto
- Nurse, Department of Nursing, Sin-ai nursing home, Hiroshima, Japan
| | - C Mihara
- Assistant Professor, Professor, Department of Nutritional Sciences Faculty of Human Ecology, Yasuda Women's University, Hiroshima, Japan
| |
Collapse
|
25
|
Kawaida Y, Fukudome K, Uejima A, Nishi T, Hata K, Taniyama S, Oowatashi A, Yone K. Virtual reality training for fall prevention. Physiotherapy 2015. [DOI: 10.1016/j.physio.2015.03.3593] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
26
|
Hata K, Kiyama R, Ishido Y, Yone K, Fukudome K, Nishi T, Kawaida Y. Estimation of hip joint loading during gait before and after total hip arthroplasty using a musculoskeletal modeling system. Physiotherapy 2015. [DOI: 10.1016/j.physio.2015.03.3358] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
27
|
Nishi T, Fukudome K, Yone K, Maeda T, Hata K, Kawaida Y. Evaluation of active upper limb ability in cervical spondylotic myelopathy via an artificial neural network. Physiotherapy 2015. [DOI: 10.1016/j.physio.2015.03.1990] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
28
|
Takenaka A, Yoneda M, Seki T, Uema M, Kooriyama T, Nishi T, Fujita K, Miura R, Tsukiyama-Kohara K, Sato H, Kai C. Characterization of two recent Japanese field isolates of canine distemper virus and examination of the avirulent strain utility as an attenuated vaccine. Vet Microbiol 2014; 174:372-381. [DOI: 10.1016/j.vetmic.2014.10.024] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2014] [Revised: 10/21/2014] [Accepted: 10/27/2014] [Indexed: 10/24/2022]
|
29
|
Abstract
This paper presents a motion planning method which provides a complete whole body trajectory of a humanoid robot traveling in a complex environment with various life items, steps, slopes, gates, walls, etc. A two-stage planning scheme is employed to simplify the problem of discontinuously changing dynamical constraints, where a sequence of double-support postures is planned in the first stage, and a continuous and smooth trajectory interpolates it in the second stage. RRT is utilized in the both stages in order to exploit the whole body with a large degree-of-freedom and perform in such a three-dimensionally intricate field. An inevitable issue of that random-sampling-based approach is that the searched trajectory is necessarily jaggy and detouring. The proposed method includes effective post-processing techniques for each stage, which are mandatory in practice. In the first stage, a necessary condition is that any pair of adjacent postures has to share one supporting foot as the pivot. A key idea is to insert intermediate postures between a pair of non-adjacent milestones with a cross-combination of the support feet to bypass and average a sequence of double-support transitions. The optimal sequence of the possible transitions is found by applying Dijkstra's method. In the second stage, an idea of the center of mass (COM)-enforcement to artificially constrain the trajectory of COM on one based on the mass-concentrated approximation is proposed, expecting that a solution can be found on this manifold. A continuous and smooth trajectory which satisfies the geometric constraint is planned by RRT and NURBS interpolation, and then, the temporal property of the trajectory is adjusted based on the dynamic programming to satisfy the dynamical constraint without breaking the geometric constraint. The performance was examined in a mock field of a living room. Comparing with a naive method only with RRT-connect, it substantially shortened the total travel distance in many cases. It also succeeded to plan dynamically feasible walking trajectories on that complex terrain.
Collapse
Affiliation(s)
- Toshiya Nishi
- Information Strategy Planning Division, DENSO CORPORATION, 1–1, Showa-cho, Kariya, Aichi 448-8661, Japan
| | - Tomomichi Sugihara
- Department of Adaptive Machine Systems, Graduate School of Engineering, Osaka University, 2–1 Suita, Osaka 565-0871, Japan
| |
Collapse
|
30
|
Yoshida T, Oishi K, Nishi T, Ishibashi T. Nd3-xBixFe4GaO12(x = 2, 2.5) films on glass substrates prepared by MOD method. EPJ Web of Conferences 2014. [DOI: 10.1051/epjconf/20147505009] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
31
|
Ito E, Ozawa S, Kijima H, Kazuno A, Miyako H, Nishi T, Chino O, Shimada H, Tanaka M, Inoue S, Inokuchi S, Makuuchi H. Clinicopathological significance of laminin-5γ2 chain expression in superficial esophageal cancer. Dis Esophagus 2014; 27:463-9. [PMID: 22978811 DOI: 10.1111/j.1442-2050.2012.01416.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
The glycoprotein laminin 5γ2 chain (LN-5γ2) has recently become a focus of increased interest and investigation as a marker of invasion in gastrointestinal malignancies. We investigated the significance of LN-5γ2 expression as a prognostic factor in superficial esophageal cancer. The study population consisted of 87 patients who had undergone a transthoracic esophagectomy and three-field lymphadenectomy for the treatment of superficial esophageal cancer at Tokai University Hospital. Formalin-fixed, paraffin-embedded sections of the resected specimens were examined using immunohistochemical staining and hematoxylin and eosin staining to assess the correlations between the LN-5γ2 expression pattern and the clinicopathological factors (age, sex, T-factor, N-factor, ly-factor, v-factor, degree of differentiation, infiltrative growth pattern, tumor node metastasis classification of malignant tumors [TNM] stage, etc.) and the patient outcome. The expression pattern of LN-5γ2 was classified into an extracellular type (E type), characterized by the staining of extracellular matrix such as the basement membrane and the stroma (31 cases, 35.6%), and a cytoplasmic type (C type), characterized by the staining of the cytoplasm in the cancer cells (56 cases, 64.6%). The expression pattern was not correlated with any of the clinicopathological factors that were assessed. However, univariate analyses of the survival analysis data showed that the N-factor (P = 0.011), TNM stage (P = 0.011), and LN-5γ2 C type (P = 0.017) were prognostic factors. A multivariate analysis revealed that the N-factor (P = 0.049) and LN-5γ2 C type (P = 0.048) were prognostic factors. In the survival analysis, a univariate analysis of the 75 T1b cases also showed that the N-factor (P = 0.048), TNM stage (P = 0.048), and LN-5γ2 C type (P = 0.029) were prognostic factors, while a multivariate analysis showed that the LN-5γ2 C type (P = 0.035) was a prognostic factor. The C type expression of LN-5γ2, i.e. confined to the cytoplasm, was correlated with an unfavorable outcome among the patients with superficial esophageal cancer in the present series. Observation of the LN-5γ2 expression pattern may be useful for the diagnosis of highly malignant tumors.
Collapse
Affiliation(s)
- E Ito
- Department of Gastroenterological Surgery, Tokai University School of Medicine, Isehara, Kanagawa, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Kawabata Y, Nishi T, Tanaka T, Tajima Y. Safety and Feasibility of a Pancreaticoduodenectomy with Total Meso-Pancreatoduodenum Excision: Analysis in Various Periampullary Disorders. Hepatogastroenterology 2014; 61:821-827. [PMID: 26176080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
BACKGROUND/AIMS This study aimed to evaluate the safety and feasibility of a pancreaticoduodenectomy with total meso-pancreatoduodenum excision (tMPDe) as an new anatomical concept. METHODOLOGY A total of 90 patients underwent PD for various periampullary diseases. Of these, 52 patients received a conventional PD (cPD), while 38 patients underwent a tMPDe. Surgical outcomes were compared between the two study groups. RESULTS Operative time was equivalent in the two groups; however, the estimated blood loss (cPD, 1360 ml; tMPDe, 995 ml; median, P = 0.026) and blood transfusion rate (cPD, 63%; tMPDe, 31% ; P = 0.001) were significantly decreased in tMPDe. Morbidity had no significant difference between cPD and tMPDe, and tMPDe showed no characteristic complications. With regard to oncological aspects, tMPDe was superior to cPD. Risk factors analysis revealed the operative time (P = 0.003), estimated blood loss (P < 0.001), and blood transfusion (P < 0.001) to be significant predictive risk factors for postoperative morbidity but not tMPDe procedure (P = 0.794). CONCLUSIONS tMPDe is safe and superior to cPD because it is a bloodless operation with a good oncological outcome: We concluded that tMPDe should be adaptable to various periampullary diseases, including benign and low-grade malignant disorders.
Collapse
|
33
|
Denda T, Nishi T, Yamaguchi K, Kenji A, Miyata Y, Yamanaka Y, Yanai K, Hamamoto Y, Nagase M, Fujii H. A Phase II Study of the Panitumumab+ Irinotecan Therapy for Advanced / Recurrence Colorectal Cancer (Topic Study). Ann Oncol 2013. [DOI: 10.1093/annonc/mdt459.51] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
34
|
Ogura Y, Mihara C, Konagaya N, Nose Y, Sato H, Sukekane A, Yuki N, Nishi T. PP216-MON ADMINISTRATION OF ABOUND™ TO THREE ELDERLY PATIENTS WITH INTRACTABLE PRESSURE ULCER AND RENAL DYSFUNCTION. Clin Nutr 2013. [DOI: 10.1016/s0261-5614(13)60526-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
35
|
Kawabata Y, Nishi T, Tanaka T, Yano S, Tajima Y. Distal Pancreatectomy Utilizing a Flexible Stapler Closure Eliminates the Risk of Pancreas-Related Factors for Postoperative Pancreatic Fistula. Eur Surg Res 2013; 50:71-9. [DOI: 10.1159/000349977] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2012] [Accepted: 02/17/2013] [Indexed: 11/19/2022]
|
36
|
Nishi T, Takeshima H, Hamada K, Yoshizato K, Koga H, Sato K, Yamamoto K, Kitamura I, Kochi M, Kuratsu J, Saya H, Ushio Y. Neurofibromatosis 2 gene has novel alternative splicings which controls intracellular protein binding. Int J Oncol 2012; 10:1025-9. [PMID: 21533480 DOI: 10.3892/ijo.10.5.1025] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
Three novel isoforms of the neurofibromatosis 2 (NF2) gene transcripts generated from alternative splicing were identified from normal human brain, schwannoma and glioma tissues. The 3 novel transcripts lack exon 2, exons 2 and 3, exons 2-4, respectively. Recombinant isoform proteins encoded by those new transcripts have lost the previously reported ability to bind S-35-methionine labeled cellular proteins. Two of seven glioblastoma tissues expressed significantly high levels of the shorter transcripts whereas low grade astrocytomas expressed levels similar to those found in normal brain, suggesting that genomic mutation or aberrant alternative splicing of the NF2 gene may contribute to the progression of malignant gliomas.
Collapse
Affiliation(s)
- T Nishi
- KUMAMOTO UNIV,SCH MED,DEPT TUMOR GENET & BIOL,KUMAMOTO 860,JAPAN
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Yoshizato K, Kuratsu J, Takeshima H, Nishi T, Yoshimura T, Ushio Y. Increased monocyte chemoattractant protein-1 expression by tumor necrosis factor-alpha can mediate macrophage infiltration in gliomas. Int J Oncol 2012; 8:493-7. [PMID: 21544387 DOI: 10.3892/ijo.8.3.493] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
We compared the in vitro effects of various cytokines on the expression of monocyte chemoattractant protein-1 (MCP-1) in glioma cell lines and found that MCP-1 expression was highly induced by tumor necrosis factor-alpha (TNF alpha) and interleukin-1 beta. The intra-tumoral injection of TNF alpha in rat glioma model increased the in vivo expression of MCP-1 at 1 to 12 h after the injection and induced macrophage infiltration into tumor tissue. The injection of TNF alpha into post-operative tumor cavity of human malignant glioma also increased the concentration of MCP-1 in the cavity fluid at 24 to 38 h after injection. These data, together with the previous finding that the growth of transplanted MCP-1-transfected cells was significantly inhibited by infiltrated macrophages, suggest that injection of TNF alpha inhibits turner growth via the induction of MCP-1 expression.
Collapse
Affiliation(s)
- K Yoshizato
- NCI,FREDERICK CANC RES & DEV CTR,IMMUNOBIOL LAB,IMMUNOPATHOL SECT,FREDERICK,MD 21701
| | | | | | | | | | | |
Collapse
|
38
|
Toyoda K, Sato S, Koga M, Yamamoto H, Nakagawara J, Furui E, Shiokawa Y, Hasegawa Y, Okuda S, Sakai N, Kimura K, Okada Y, Yoshimura S, Hoshino H, Uesaka Y, Nakashima T, Itoh Y, Ueda T, Nishi T, Gotoh J, Nagatsuka K, Arihiro S, Yamaguchi T, Minematsu K. Run-up to participation in ATACH II in Japan. J Vasc Interv Neurol 2012; 5:1-5. [PMID: 23230457 PMCID: PMC3517030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
Intracerebral hemorrhage (ICH) is a major cause of morbidity and mortality in Japan. Seventeen Japanese institutions are participating in the Antihypertensive Treatment for Acute Cerebral Hemorrhage (ATACH) II Trial (ClinicalTrials.gov no. NCT01176565; UMIN 000006526). This phase III trial is designed to determine the therapeutic benefit of early intensive systolic blood pressure (BP) lowering for acute hypertension in ICH patients. This report explains the long run-up to reach the start of patient registration in ATACH II in Japan, including our preliminary study, a nationwide survey on antihypertensive treatment for acute ICH patients, a multicenter study for hyperacute BP lowering (the SAMURAI-ICH study), revision of the official Japanese label for intravenous nicardipine, and construction of the infrastructure for the trial.
Collapse
Affiliation(s)
- K Toyoda
- Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, 5-7-1 Fujishiro-dai, Suita 565-8565, Japan
| | - S Sato
- Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, 5-7-1 Fujishiro-dai, Suita 565-8565, Japan
| | - M Koga
- Division of Stroke Care Unit, National Cerebral and Cardiovascular Center, 5-7-1 Fujishiro-dai, Suita 565-8565, Japan
| | - H Yamamoto
- Department of Advanced Medical Technology Development, National Cerebral and Cardiovascular Center, 5-7-1 Fujishiro-dai, Suita 565-8565, Japan
| | - J Nakagawara
- Department of Neurosurgery and Stroke Center, Nakamura Memorial Hospital, Sapporo, Japan
| | - E Furui
- Department of Stroke Neurology, Kohnan Hospital, Sendai, Japan
| | - Y Shiokawa
- Department of Neurosurgery and Stroke Center, Kyorin University School of Medicine, Mitaka, Japan
| | - Y Hasegawa
- Department of Neurology, St. Marianna University School of Medicine, Kawasaki, Japan
| | - S Okuda
- Department of Neurology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan
| | - N Sakai
- Stroke Center, Kobe City Medical Center General Hospital, Kobe, Japan
| | - K Kimura
- Department of Stroke Medicine, Kawasaki Medical School, Kurashiki, Japan
| | - Y Okada
- Department of Cerebrovascular Medicine, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan
| | - S Yoshimura
- Department of Neurosurgery, Gifu University, Gifu, Japan
| | - H Hoshino
- Department of Neurology, Tokyo Saiseikai Central Hospital, Tokyo, Japan
| | - Y Uesaka
- Department of Neurology, Toranomon Hospital, Tokyo, Japan
| | - T Nakashima
- Department of Neurology, National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan
| | - Y Itoh
- Department of Neurology, Keio University School of Medicine, Tokyo, Japan
| | - T Ueda
- Department of Strokology, St. Marianna University, School of Medicine, Toyoko Hospital, Kawasaki, Japan
| | - T Nishi
- Department of Neurosurgery, Saiseikai Kumamoto Hospital, Kumamoto, Japan
| | - J Gotoh
- Department of Neurology, Saiseikai Yokohamashi Tobu Hospital, Yokohama, Japan
| | - K Nagatsuka
- Department of Neurology, National Cerebral and Cardiovascular Center, 5-7-1 Fujishiro-dai, Suita 565-8565, Japan
| | - S Arihiro
- Division of Stroke Care Unit, National Cerebral and Cardiovascular Center, 5-7-1 Fujishiro-dai, Suita 565-8565, Japan
| | - T Yamaguchi
- National Cardiovascular Center, Osaka, Japan
| | - K Minematsu
- Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, 5-7-1 Fujishiro-dai, Suita 565-8565, Japan
| |
Collapse
|
39
|
Kawabata Y, Tanaka T, Nishi T, Monma H, Yano S, Tajima Y. Appraisal of a total meso-pancreatoduodenum excision with pancreaticoduodenectomy for pancreatic head carcinoma. European Journal of Surgical Oncology (EJSO) 2012. [DOI: 10.1016/j.ejso.2012.04.007 union all select null,null,null,null,null#] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
40
|
Kawabata Y, Tanaka T, Nishi T, Monma H, Yano S, Tajima Y. Appraisal of a total meso-pancreatoduodenum excision with pancreaticoduodenectomy for pancreatic head carcinoma. European Journal of Surgical Oncology (EJSO) 2012. [DOI: 10.1016/j.ejso.2012.04.007 waitfor delay '0:0:5'-- yckn] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/30/2022]
|
41
|
Kawabata Y, Tanaka T, Nishi T, Monma H, Yano S, Tajima Y. Appraisal of a total meso-pancreatoduodenum excision with pancreaticoduodenectomy for pancreatic head carcinoma. Eur J Surg Oncol 2012. [DOI: 10.1016/j.ejso.2012.04.007 union all select null,null-- gyaq] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/30/2022] Open
|
42
|
Kawabata Y, Tanaka T, Nishi T, Monma H, Yano S, Tajima Y. Appraisal of a total meso-pancreatoduodenum excision with pancreaticoduodenectomy for pancreatic head carcinoma. European Journal of Surgical Oncology (EJSO) 2012. [DOI: 10.1016/j.ejso.2012.04.007 order by 1-- tjwi] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/30/2022]
|
43
|
Kawabata Y, Tanaka T, Nishi T, Monma H, Yano S, Tajima Y. Appraisal of a total meso-pancreatoduodenum excision with pancreaticoduodenectomy for pancreatic head carcinoma. Eur J Surg Oncol 2012. [DOI: 10.1016/j.ejso.2012.04.007 waitfor delay '0:0:5'] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/30/2022] Open
|
44
|
Kawabata Y, Tanaka T, Nishi T, Monma H, Yano S, Tajima Y. Appraisal of a total meso-pancreatoduodenum excision with pancreaticoduodenectomy for pancreatic head carcinoma. European Journal of Surgical Oncology (EJSO) 2012. [DOI: 10.1016/j.ejso.2012.04.007 union all select null,null,null,null,null,null,null-- lhhv] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
45
|
Kawabata Y, Tanaka T, Nishi T, Monma H, Yano S, Tajima Y. Appraisal of a total meso-pancreatoduodenum excision with pancreaticoduodenectomy for pancreatic head carcinoma. European Journal of Surgical Oncology (EJSO) 2012. [DOI: 10.1016/j.ejso.2012.04.007 union all select null-- hldo] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/30/2022]
|
46
|
|
47
|
Kawabata Y, Tanaka T, Nishi T, Monma H, Yano S, Tajima Y. Appraisal of a total meso-pancreatoduodenum excision with pancreaticoduodenectomy for pancreatic head carcinoma. Eur J Surg Oncol 2012. [DOI: 10.1016/j.ejso.2012.04.007 union all select null,null,null-- bbzg] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
48
|
|
49
|
Kawabata Y, Tanaka T, Nishi T, Monma H, Yano S, Tajima Y. Appraisal of a total meso-pancreatoduodenum excision with pancreaticoduodenectomy for pancreatic head carcinoma. Eur J Surg Oncol 2012. [DOI: 10.1016/j.ejso.2012.04.007 and 3646=4631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/30/2022] Open
|
50
|
Kawabata Y, Tanaka T, Nishi T, Monma H, Yano S, Tajima Y. Appraisal of a total meso-pancreatoduodenum excision with pancreaticoduodenectomy for pancreatic head carcinoma. European Journal of Surgical Oncology (EJSO) 2012. [DOI: 10.1016/j.ejso.2012.04.007 and 1328=1328-- scxc] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/30/2022]
|